Professor Márta KorbonitsProfessor in Endocrinology and Deputy Director of the WHRICentre: Endocrinology Email: m.korbonits@qmul.ac.ukTelephone: +44(0) 20 7882 6238Website: https://www.qmul.ac.uk/fipa-patients/ProfileResearchPublicationsSponsorsCollaboratorsNewsDisclosuresProfile ORCID iD: 0000-0002-4101-9432 Márta Korbonits graduated in Medicine in Budapest and undertook her early clinical training at the Internal Medicine Department of the Postgraduate Medical School, Budapest. She joined the Department of Endocrinology at St. Bartholomew’s Hospital under the mentorship of Professors Ashley Grossman and Michael Besser. Her MD concentrated on the effects of growth hormone secretagogues on hypothalamic hormone release, while her PhD studies explored the nature and causes of pituitary tumorigenesis. She was awarded an MRC Clinician Scientist Fellowship, and commenced studies that produced novel insights into ghrelin physiology and genetics. Her findings related to the regulation of the metabolic enzyme AMPK by ghrelin, cannabinoid and glucocorticoid opened a new aspect of hormonal regulation of metabolism. She is working on novel aspects of the genetics of endocrine tumours as well as metabolic consequences of hormonal imbalances. She is Professor of Endocrinology and Metabolism, Centre Lead of Endocrinology and Deputy Director of the William Harvey Research Institute at Barts and the London School of Medicine, Queen Mary University of London and Honorary Consultant at Barts Health NHS Trust. Prof Korbonits’s publications and metrics can be found on Google Scholar. Professor Korbonits continues to integrate human studies alongside with laboratory-based research and has pioneered several projects in translational medicine. Over the last decade her major research focus involves the clinical and scientific aspects of familial isolated pituitary adenomas. In addition to her basic research, she looks after patients with endocrine diseases in St. Bartholomew’s Hospital and undertakes wide-ranging undergraduate and postgraduate teaching activities as well as supervision of MSc and PhD students. Professor Korbonits has received several awards, including the Nicholas T. Zervas Lectureship in Pituitary and Neuroendocrine Disorders at Massachusetts General Hospital (2010), the Society for Endocrinology Medal (2013), the Endocrine Society’s Delbert Fischer award (2015), the Hadden Lecture Prize, Irish Endocrine Society (2017), the Harrison Lecture Prize, Endocrine Society of Australia (2017) and the Estelle Wolfson award from the Royal College of Physicians (2018). She has been invited Professor at University of Colorado 2019 and had the KROC Visiting Professorship Award, Mayo Clinic in 2020, and is the Royal College of Physicians of Edinburgh keynote lecturer, Edinburgh in 2020. She supports the endocrine community’s learned societies: served as the Conference Program Secretary for the Society for Endocrinology, was Board member for Pituitary Society and European Neuroendocrine Society and Chair of the Science Committee of the European Society of Endocrinology.She is a current or past Editorial Board member of the Journal of Clinical Endocrinology and Metabolism, Journal and Neuroendocrinology, Pituitary and Journal of Endocrinology and Associate Editor of Scientific Reports, Annals of Human Genetics and the Journal of the Endocrine Society. She is a member of the Medical Research Council (MRC) Fellowship Committee and Head of the Society of Endocrinology Leadership program. ResearchGroup membersDr Sayka Barry and Dr Federica Begalli (Postdoctoral Fellows); Dr Chung Lim (Clinical Training Fellow), Dr Kesson Magid (Database Manager); Ms Anisha Mistry (PhD student); Mr Solomon Muna (Clinical Fellow); Ms Oniz Suleyman (Senior technician); Dr Nicola Tufton (Clinical Training Fellow). Writing up status: Dr Donato Iacovazzo (Diabetes UK Clinical Training Fellow); Ms Karen Young (MRC Clinical Training Fellow) Close collaborator: Dr Oliver Haworth (Lecturer) Selected Past Lab MembersDr Blerina Kola (Clinical Training Fellow); Dr Chrysanthia Leontiou (PhD student); Dr Craig Stiles (Wellcome Clinical Training Fellow); Dr Daniela Aflorei (Clinical Training Fellow); Dr Edwin Garcia (Postdoctoral Fellow); Dr Francesco Ferrau (Visiting Clinical Fellow); Dr Giampaolo Trivellin (Postdoctoral Fellow); Dr Harvinder Chahal (MRC Clinical Training Fellow); Dr Erika Hubina (Clinical Training Fellow); Dr Ida Pernicova (Clinical Training Fellow); Dr Julia Thomas (Clinical Training Fellow); Dr Laura Hernandez-Ramirez (Clinical Training Fellow); Dr Marton Doleschall (Postdoctoral Fellow); Dr Mirjam Christ-Crain (Clinical Training Fellow); Dr Pam Gabrovska (Database Manager); Dr Serban Radian (Marie Curie Research Fellow); Alejandro Ibanez Costa (Postdoctoral Fellow); Dr Antonia Solomou (Postdoctoral Fellow); Dr Francisca Palou (Clinical Fellow); Dr David Collier and Dr Amy Ronaldson (Database Managers); Tatsuya Komogata (visiting scientist); Dr Sherine Awad (Bioinformatician) Pituitary and Neuroendocrine GroupProf Korbonits’ research group concentrates on the etiology and tumorigenic process of familial and sporadic pituitary adenomas. She set up a website for this disease for patients and health care professionals (https://www.qmul.ac.uk/fipa-patients/) and established the International FIPA consortium to study the clinical, genetic and molecular characteristics of these patients. The groups’ major focus concerns the mechanism by which loss-of-function AIP mutations cause particularly aggressive adenomas at a young age, studies centered around the analysis of human samples and new in vivo models of human disease (in collaboration with Carles Gaston-Massuet), including in the fruit fly. In parallel, in vitro assays are helping to complete the cycle of pituitary adenoma variant identification to pathological understanding of disease etiologies. The group has shown that an AIP mutation (Arg304Stop) that was introduced into the DNA of a resident of Northern Ireland some 2500 years ago helps explain the long history of Irish giants (Figure 1). Their genetic studies, which have established that this founder mutation still survives in this population today (Figure 2) (see further details at: https://www.qmul.ac.uk/fipa-patients/irish-giants/), provides an excellent example of how genetic screening, followed by clinical screening of carrier family members can identify pre-symptomatic patients, leading to earlier diagnosis and more personalized treatment and a better long-term prognosis. These data has now been confirmed in our large cohort (Marques, JCEM, 2020). The group are now investigating a second founder mutation due to replication slippage mechanism (Figure 3) affecting nine families living in three different countries (UK, France and USA) but all originating from a single founder probably in England from several hundred years ago (Figure 4). Figure 1. AIP Mutations and Gigantism. First panel. 18th century patient with gigantism due to a mutation of AIP (aryl hydrocarbon receptor interacting protein) beside his twin cousins who also had gigantism, in an etching by John Kay (1742–1826) (National Portrait Gallery, London) (Chahal, NEJM, 2011). Middle panel. Ribbon representation of the crystal structure of human AIP (based on data published in Morgan, PlosOne, 2012 and Linnert, Biomol.NMR Assign., 2012) with the stop mutation from the 18th-century patient marked in red. Right-hand panel. A hand of a 4th-year male medical student (172 cm tall) compared to the tracing of the hand of an Irish patient from the 18th century with gigantism (tracing from Frankom, G; Musgrave, J.H. The Irish giant, 1974, Duckworth, London). Figure 2. In Ireland, the highest geographical concentration of the Irish Giant AIP R304* allele is found in Mid Ulster (red dotted line). R304* carriers: unaffected (green columns) and patients with somatotrophinomas (red). AIPmut-negative patients with somatotrophinomas (AIP-neg GH, blue columns). Only current residents of Ireland were screened. R304*-positive patients with other pituitary adenoma types (n=5) are not shown. Each small graph summarizes data from the underlying region. From Radian S et al, Human Mutation 2017. Figure 3. In-frame seven amino acid duplication of aryl hydrocarbon receptor protein (AIP) reduces protein stability and interaction with Heat Shock Protein 90 (HSP90) A) Schematic of the suggested replication slippage mechanism creating the c.805_825dup, p.F269_H275duplication. The purple and blue colorings match the sequences in B). During DNA replication, the primer strand containing the newly synthesized second repeat transiently dissociates from the template, slips backwards and then re-associates at the first short direct repeat of the template strand, resulting in a misaligned configuration. Continued DNA synthesis is envisaged to lead to the insertion of the intervening sequence and the second direct repeat, resulting in the duplicated allele. B) DNA sequences of WT AIP (bottom) and of the mutated allele (top). N.B. the two 9 base-pair long repeats, the 5’ one marked in purple (caaggcctac) and the 3’ one marked in blue (caaggcccac). The duplicated sequence (italic) introduces additional amino acids in the protein binding domain TPR3. C) Cartoon representation of the atomic structure of AIP, highlighting the two pairs of helices forming the TPR2 (light orange) and TPR3 protein binding domains. D) Close up of structures mediating binding between WT AIP and HSP90 (blue peptide) and simulation of the effect of the seven amino-acid AIP duplication (purple) on the AIP structure mediating HSP90 binding. Residue K266 (green), in the wild-type AIP interacts with the HSP90 peptide (or with TOMM20 peptide). From Salvatori EJE 2017. Figure 4. Pedigrees of the English founder AIP c.805_825dup (p.F269_H275dup) mutation and geographical locations. From Salvatori EJE 2017. Recent research projects Hormone effects and metabolismNearly one percent of the general population and 2.5% of those above 70 years of age are on long-term glucocorticoid treatment for a chronic inflammatory disease. Many of these patients develop iatrogenic Cushing syndrome, causing significant metabolic, cardiovascular and musculoskeletal morbidity for which there is a treatment need but no current solution. We conducted a clinical trial exploring a concept arisen from our previous experimental studies (Christ-Crain, Faseb J, 2008, Pubmed 18198220 and Kola JCEM, 2008, Pubmed 18782871): many of the changes seen in glucocorticoid excess correspond to metabolic steps regulated by the enzyme 5’AMP-activated protein kinase (AMPK), a key regulator of energy metabolism and one of the well-recognized mediators of metformin’s mode of action (Pernicova & Korbonits, Nature Rev Endocrinal, 2014). We assessed the effect of metformin in glucocorticoid-treated patients. Despite the relatively short duration of the study, we found, in addition to glucose-related positive outcomes, beneficial effects in several cardiovascular, metabolic, bone and inflammatory parameters. Key findings with significant relevance to healthcare were the lower frequency of pneumonia in the metformin group compared with placebo, reduced overall rate of moderate-to-severe infections and, most significantly, lower all-cause hospital admissions. Our data could have immediate clinical relevance as the simple treatment suggestion – metformin treatment for patients on glucocorticoid treatment, even if they do not have diabetes. The results leading to clinically relevant significant impact on a large number of patients on long-term glucocorticoids via improving their treatment-related complications and cardiovascular prognosis. Although there are a large number of patients treated with glucocorticoids in the UK, Europe and US, there is increasing use of biologics or other steroid-sparing agents. However, other parts of the world still rely heavily on glucocorticoids. A safe, cheap and effective prevention/treatment of major metabolic complications of long-term glucocorticoid use is eagerly awaited, and our study showed that metformin could be served as a treatment. The data has been published in Lancet Diabetes and Endocrinology with an accompanying editorial: Metformin: the white knight fighting corticosteroid side-effects. Pernicova, I., Kelly, S., Ajodha, S., Sahdev, A., Bestwick, J.P., Gabrovska, P., Akanle, O., Ajjan, R., Kola, B., Stadler, M., Fraser, W., Christ-Crain, M., Grossman, A.B., Pitzalis, C. & Korbonits, M. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes and Endocrinology 2020; 8: 278-291. ^10.1016/S2213-8587(20)30021-8 Download: Metformin: the white knight fighting corticosteroid side effects, Reincke Lancet D&E 2020 Comment [PDF 130KB] Media coverage: Daily diabetes pill which costs just 15p could end the dreaded 'moon face' side effect of steroid medication which causes the face to swell up, Daily Mail, 14 March 2020 Schematic representation of how AIP deficiency leads to the aggressive phenotype in AIPpos tumoursCrosstalk between AIPpos tumours and the tumour microenvironment. AIPpos tumours have EMT signatures and increased immune cell contents, cytokines and abundant vascular structures which create a tumour supportive microenvironment to promote aggressive tumour growth. The upregulation of the CCL5 in the AIPpos tumours and the in vitro data presented suggest that CCL5, secreted by the tumour cells, may contribute to the recruitment of macrophages and initiate bidirectional paracrine signalling loops which facilitate increased migratory/invasive potential of the tumour cells. Our findings indicate that AIP deficiency in pituitary cells drives invasion through the induction of EMT and immune cells recruitment. The tumour microenvironment of pituitary tumoursPituitary tumour cells release different cytokines, particularly chemokines (including IL-8, CCL2, CCL3, CCL4, CXCL10, CXCL1), directly into the tumour microenvironment promoting the recruitment and infiltration of immune cells, including macrophages, lymphocytes and neutrophils. These infiltrating immune cells increase the growth of the tumour. Fibroblasts within the tumour are also able to secrete cytokines, such as IL-6, into the tumour microenvironment, which leads to increased invasion of pituitary tumour cells or the surrounding tissues. Marques, P., Barry, S., Carlsen, E. et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. acta neuropathol commun 7, 172 2019. https://doi.org/10.1186/s40478-019-0830-3 Marques, P., Barry, S., Carlsen, E. et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness, Endocrine-Related Cancer, 26, 12 2019. https://doi.org/10.1530/ERC-19-0327 BCL6 – protein supporting lymphoma growth FBXO11 – protein attached ubiquitin chain to BCL6 Ub- ubiquitin molecules forming a chain UCLH1 – protein which cuts off ubiquitin chain from BCL6 Proteasome - the cell system to degrade proteins AIP - the bad guyWhile in pituitary tumours AIP seem to be fending off cancer, in lymphoma (a certain type of blood cancer) AIP seems to support those cells which generate cancerous growth. BCL6, a protein supporting cell proliferation and AIP are both highly expressed in a certain type of lymphoma (Diffuse Large B cell Lymphoma). Proteins get degraded if a particular molecule-chain (ubiquitin-chain) is attached to them and escape degradation if this chain is cut-off. We found that AIP supports the enzyme which cuts off the ubiquitin-chain from BCL6. Lack of AIP results increased amount on ubiquitin-chain associated BCL6 which then results in BCL6 degradation. This new mechanism could be exploited in the treatment of B-cell lymphoma. Sun, D., Stopka-Farooqui, U., Barry, S., Aksoy, E., Parsonage, G., Vossenkamper, A., Capasso, M., Wan, X., Norris, S., Marshall, J.L., Clear, A., Gribben, J., MacDonald, T.T., Buckley, C.D., Korbonits, M. & Haworth, O. Aryl hydrocarbon receptor interacting protein maintains germinal center B cells through suppression of BCL6 degradation [PDF 4,781KB]. Cell Reports 2019; 27: 1461-1471 e1464. ^10.1016/j.celrep.2019.04.014Publications Gupta A, Kasaliwal R, Das L et al. (publicationYear). Ectopic acromegaly with tumoral range hyperprolactinemia and apoplexy with a dramatic regression of pituitary hyperplasia. nameOfConference DOI: 10.3389/fendo.2024.1473167 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100921 Loughrey PB, Greene C, McCombe KD et al. (2024). Assessment of Ki‐67 and mitoses in pituitary neuroendocrine tumours—Consistency counts. nameOfConference DOI: 10.1111/bpa.13285 QMRO: qmroHref Loughrey PB, Herron B, Cooke S et al. (2024). Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland. nameOfConference DOI: 10.1530/erc-24-0028 QMRO: qmroHref Hernández-Ramírez LC, Perez-Rivas LG, Theodoropoulou M et al. (2024). An Update on the Genetic Drivers of Corticotroph Tumorigenesis. nameOfConference DOI: 10.1055/a-2337-2265 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97522 MacFarlane J, Korbonits M (2024). Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess. nameOfConference DOI: 10.1016/j.beem.2024.101910 QMRO: qmroHref Bizzi MF, Drummond JB, Pinheiro SVB et al. (2024). Activated AMP-protein kinase (pAMPK) is overexpressed in human somatotroph pituitary adenomas. nameOfConference DOI: 10.1016/j.mce.2024.112318 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100331 Teja KVR, Malhotra B, Vogel M et al. (2024). Normative Data for Insulin-Like Growth Factor 1 in Healthy Children and Adolescents From India. nameOfConference DOI: 10.1210/clinem/dgae340 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97000 Stelmachowska-Banaś M, Barry S, Angurala I et al. (publicationYear). Novel mutations causing pachydermoperiostosis - hormonal and phenotypic alterations. nameOfConference DOI: 10.1530/endoabs.99.p513 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97521 Marques P, Sapinho I, Korbonits M (publicationYear). Pseudoacromegaly - a challenging entity in the endocrine clinic: why you need to know about it?. nameOfConference DOI: 10.1530/endoabs.99.ep210 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97742 Carreira A, Muna S, Grossman AB et al. (2024). Beware of epistaxis: fatal pseudoaneurysm rupture 30 years after treatment of acromegaly. nameOfConference DOI: 10.1136/bcr-2023-258533 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/96438 Marques P, Sapinho I, Korbonits M (2024). Pseudoacromegaly—A challenging entity in the endocrine clinic: A systematic review. nameOfConference DOI: 10.1111/cen.15053 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/96499 Das L, Laway BA, Sahoo J et al. (2024). Bone mineral density, turnover, and microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography in patients with Sheehan’s syndrome. nameOfConference DOI: 10.1007/s00198-024-07062-z QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95915 Janssen H, Jhanji S, Oliver NS et al. (2024). Ward monitoring 4.0: real-time metabolic insights from continuous glucose monitoring into perioperative organ dysfunction. nameOfConference DOI: 10.1016/j.bja.2024.01.039 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95278 Bogusławska A, Godlewska M, Hubalewska-Dydejczyk A et al. (2024). Tall stature and gigantism in adult patients with acromegaly. nameOfConference DOI: 10.1093/ejendo/lvae019 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95279 Korbonits M, Blair JC, Boguslawska A et al. (2024). Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations. nameOfConference DOI: 10.1038/s41574-023-00948-8 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95281 Korbonits M, Blair JC, Boguslawska A et al. (2024). Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases. nameOfConference DOI: 10.1038/s41574-023-00949-7 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95280 Miller H, Harman D, Aithal GP et al. (2024). Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study. nameOfConference DOI: 10.1136/bmjopen-2023-074918 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/94159 Ali M, Rai A, Howarth S et al. (2024). An unusual phenocopy for postmenopausal ovarian hyperandrogenism: LH‐driven testosterone secretion by adrenal adenoma expressing luteinising hormone‐chorionic gonadotrophin receptor. nameOfConference DOI: 10.1111/cen.15019 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95282 Akkuş G, Korbonits M (2023). Genetic Testing in Hereditary Pituitary Tumors. nameOfConference DOI: 10.1016/j.arcmed.2023.102920 QMRO: qmroHref Garcia-Rendueles AR, Chenlo M, Oroz-Gonjar F et al. (2023). Correction: RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas. nameOfConference DOI: 10.1038/s41388-023-02862-9 QMRO: qmroHref Wang X, Haworth O, Abdi-Aziz N et al. (publicationYear). Aryl hydrocarbon receptor-interacting protein (aip) loss causes failure-to-thrive and cardiac defects in zebrafish. nameOfConference DOI: 10.1530/endoabs.94.oc3.6 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/92739 Rai A, Begalli F, Barry S et al. (publicationYear). CDC42: a potential therapeutic target of clinically non-functioning pituitary neuroendocrine tumours. nameOfConference DOI: 10.1530/endoabs.94.oc3.1 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/92759 Sanpawithayakul K, Mistry A, Rai A et al. (publicationYear). Hindering the progression of cardiac fibrosis in acromegaly - the role of somatostatin receptor ligands. nameOfConference DOI: 10.1530/endoabs.94.p363 QMRO: qmroHref Barry S, Rai A, Haworth O et al. (publicationYear). Integrated multi-omics data reveals distinct regulatory signatures and signaling pathways of aryl hydrocarbon receptor interacting protein (AIP) knockout cells. nameOfConference DOI: 10.1530/endoabs.94.p80 QMRO: qmroHref Wang X, Leggieri A, Anagianni S et al. (2023). THU079 Danio Rerio (Zebrafish): A New Model Of AIP Loss Of Function. nameOfConference DOI: 10.1210/jendso/bvad114.1159 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91399 Bogusławska A, Godlewska M, Rzepka E et al. (publicationYear). The genetic background of acromegaly in a tertiary referral centre in Krakow, Poland. nameOfConference DOI: 10.1530/endoabs.93.oc25 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/96099 Aung Y, Kokotsis V, Yin KN et al. (publicationYear). Key features of puberty onset and progression can help distinguish self-limited delayed puberty from congenital hypogonadotrophic hypogonadism. nameOfConference DOI: 10.3389/fendo.2023.1226839 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91106 Lessey AJ, Mirczuk SM, Chand AN et al. (publicationYear). Pharmacological and Genetic Disruption of C-Type Natriuretic Peptide (nppcl) Expression in Zebrafish (Danio rerio) Causes Stunted Growth during Development. nameOfConference DOI: 10.3390/ijms241612921 QMRO: qmroHref Gan H-W, Morillon P, Albanese A et al. (2023). National UK guidelines for the management of paediatric craniopharyngioma. nameOfConference DOI: 10.1016/s2213-8587(23)00162-6 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/90260 Canton APM, Tinano FR, Guasti L et al. (2023). Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study. nameOfConference DOI: 10.1016/s2213-8587(23)00131-6 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/89521 Burren CP, Williams G, Coxson E et al. (2023). Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism. nameOfConference DOI: 10.1210/jcemcr/luad028 QMRO: qmroHref Sanpawithayakul K, Czibik G, Korbonits M (2023). Live Fast, Die Young?. nameOfConference DOI: 10.1210/clinem/dgad349 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/89064 Sanpawithayakul K, Korbonits M (2023). Metabolic complications of glucocorticoids – Prevention by metformin. nameOfConference DOI: 10.1016/j.ando.2023.05.002 QMRO: qmroHref Christ E, Iacovazzo D, Korbonits M et al. (2023). Insulinomatosis: new aspects.. nameOfConference DOI: 10.1530/erc-22-0327 QMRO: qmroHref Stelmachowska-Banaś M, Ostrowska M, Goszczyński TM et al. (2023). Macro-GH – A clinical entity causing a diagnostic challenge – A case report. nameOfConference DOI: 10.1016/j.cca.2023.117392 QMRO: qmroHref Sanpawithayakul K, Howard S, Korbonits M (publicationYear). Kisspeptin Kindred: Case Report and Literature Review. nameOfConference DOI: 10.1530/endoabs.90.ep713 QMRO: qmroHref Barry S, Haworth O, Rajeeve V et al. (publicationYear). Phosphoproteomics analysis of aryl hydrocarbon receptor interacting protein (AIP) knockout cells reveals AIP-mediated kinase signalling cascades. nameOfConference DOI: 10.1530/endoabs.90.p672 QMRO: qmroHref Marques P, Korbonits M (2023). Tumour microenvironment and pituitary tumour behaviour. nameOfConference DOI: 10.1007/s40618-023-02089-1 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/88520 Korbonits M (2023). Metabolic complications of glucocorticoids. Prevention by metformin. nameOfConference DOI: 10.1016/j.ando.2023.03.018 QMRO: qmroHref Khan J, Pernicova I, Nisar K et al. (2023). Mechanisms of ageing: growth hormone, dietary restriction, and metformin. nameOfConference DOI: 10.1016/s2213-8587(23)00001-3 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84864 Kaniuka-Jakubowska S, Levy MJ, Pal A et al. (2023). A study of acromegaly-associated headache with somatostatin analgesia.. nameOfConference DOI: 10.1530/erc-22-0138 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/83879 Detomas M, Altieri B, Flitsch J et al. (2023). Novel AIP mutation in exon 6 causing acromegaly in a German family. nameOfConference DOI: 10.1007/s40618-023-02031-5 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84470 Koh CH, Khan DZ, Digpal R et al. (publicationYear). The clinical outcomes of imaging modalities for surgical management Cushing’s disease – A systematic review and meta-analysis. nameOfConference DOI: 10.3389/fendo.2022.1090144 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84178 Mihai G, Korbonits M (2023). Chapter 15 Hypertension in growth hormone excess and deficiency. nameOfConference DOI: 10.1016/b978-0-323-96120-2.00017-0 QMRO: qmroHref De Silva NL, Govindapala D, Korbonits M et al. (publicationYear). Paraganglioma in a young female. Are we missing a possible inherited aetiology? A case report. nameOfConference DOI: 10.4038/sjdem.v13i2.7472 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84106 Boguszewski CL, Korbonits M, Artignan A et al. (2023). Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review. nameOfConference DOI: 10.1007/s12020-022-03227-0 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/82709 Teja R, Dutta P, Korbonits M et al. (2022). LBMON65 Generation Of Serum Insulin Like Growth Factor -1 (IGF-1) Normative Data According To Age, Tanner Staging & Bone Age In Healthy Indian Children And Adolescents With Two Different Assays: The Germinative Study. nameOfConference DOI: 10.1210/jendso/bvac150.986 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/83877 Rai A, Yelamanchi SD, Radotra BD et al. (2022). ODP368 Hyper-phosphorylation of β-catenin at Serine552: predictive marker of invasion and recurrence of Non-Functioning Pituitary Tumours (NFPTs). nameOfConference DOI: 10.1210/jendso/bvac150.1075 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/83876 Begalli F, Botta J, Collier D et al. (2022). PMON170 Treating human primary non-functioning pituitary adenoma cells with cabergoline. nameOfConference DOI: 10.1210/jendso/bvac150.1140 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/83875 Canton A, Tinano F, Guasti L et al. (2022). RF14 | PSAT120 X-Linked Central Precocious Puberty Associated with MECP2 Defects. nameOfConference DOI: 10.1210/jendso/bvac150.1331 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/83874 Wang X, Leggieri A, Anagianni S et al. (publicationYear). A zebrafish model of AIP loss of function. nameOfConference DOI: 10.1530/endoabs.86.p239 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/82564 Benjamin LP, Suleyman O, Begalli F et al. (publicationYear). Aberrant cyclic GMP-AMP synthase stimulator of interferon genes signalling in an AIP mutant cell line. nameOfConference DOI: 10.1530/endoabs.86.p97 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84182 Rai A, Yelamanchi SD, Barry S et al. (publicationYear). Identification of differentially activated pathways in recurrent non-functioning pituitary tumours using quantitative proteomics and bioinformatics analysis. nameOfConference DOI: 10.1530/endoabs.86.op3.2 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84185 Angurala I, Barry S, Rice T et al. (publicationYear). Identifying and characterising variants in patients with pachydermoperiostosis. nameOfConference DOI: 10.1530/endoabs.86.p106 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84186 E RJ, Pinheiro-Machado CA, Tinano F et al. (publicationYear). Variants in Methyl-CpG-binding protein 2 (MECP2) are associated with X-Linked Central Precocious Puberty. nameOfConference DOI: 10.1530/endoabs.86.p343 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/83878 Burman P, Trouillas J, Losa M et al. (2022). Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. nameOfConference DOI: 10.1530/eje-22-0440 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84181 Rai A, Yelamanchi SD, Radotra BD et al. (publicationYear). Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours. nameOfConference DOI: 10.1186/s40478-022-01441-5 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/81441 M C, J V, C B et al. (publicationYear). Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline.. nameOfConference DOI: 10.1530/ey.19.1.13 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84180 Haworth O, Korbonits M (2022). AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene. nameOfConference DOI: 10.1038/s41416-022-01964-7 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/81439 Loughrey PB, Roncaroli F, Healy E et al. (2022). Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours. nameOfConference DOI: 10.1530/erc-22-0157 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/81948 Mihai G, Korbonits M (2022). Pituitary Disorders Affecting Linear Growth: Tall Stature. nameOfConference DOI: 10.1007/978-3-030-99918-6_2 QMRO: qmroHref (2022). Correction to: “Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases”. nameOfConference DOI: 10.1210/clinem/dgac491 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84160 Salehidoost R, Korbonits M (2022). Glucose and lipid metabolism abnormalities in Cushing's syndrome. nameOfConference DOI: 10.1111/jne.13143 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/80491 Fallo F, Di Dalmazi G, Beuschlein F et al. (2022). Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. nameOfConference DOI: 10.1097/hjh.0000000000003252 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/80918 Rak-Makowska B, Khoo B, Gupta PS et al. (2022). Ockham’s Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. nameOfConference DOI: 10.1210/jendso/bvac083 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/79187 Peixe C, Sánchez-García M, Grossman AB et al. (2022). Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly. nameOfConference DOI: 10.1016/j.ghir.2022.101467 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/79445 Malhotra B, Teja KR, Bhadada S et al. (publicationYear). Age and puberty based IGF-1 normative data in healthy children from North India.. nameOfConference DOI: 10.1530/endoabs.81.ep698 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/82024 Luiz BC, Korbonits M, Artignan A et al. (publicationYear). Independent injection vs healthcare-setting administration of somatostatin analogues: A systematic literature review. nameOfConference DOI: 10.1530/endoabs.81.p411 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/81949 Stelmachowska-Banas M, Ostrowska M, Goszczyński T et al. (publicationYear). Macro-GH - a novel clinical entity causing a diagnostic challenge - a case report. nameOfConference DOI: 10.1530/endoabs.81.rc4.2 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/81950 Potorac I, Bonneville J-F, Daly AF et al. (2022). Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. nameOfConference DOI: 10.1210/clinem/dgac274 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/82141 Neumann U, van der Linde A, Krone RE et al. (publicationYear). Treatment of congenital adrenal hyperplasia in children aged 0–3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure. nameOfConference DOI: 10.1530/eje-21-1085 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/77544 Johannsson G, Touraine P, Feldt-Rasmussen U et al. (2022). Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. nameOfConference DOI: 10.1210/clinem/dgac199 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/78008 Coopmans EC, Korbonits M (2022). Molecular genetic testing in the management of pituitary disease. nameOfConference DOI: 10.1111/cen.14706 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/78006 Bogusławska A, Gilis-Januszewska A, Korbonits M (2022). Genetics of Pituitary Adenomas. nameOfConference DOI: 10.1007/978-3-030-90475-3_4 QMRO: qmroHref Cuccaro RT, Hughes I, Cools M et al. (2022). 46,XY Partial gonadal dysgenesis; diagnosis and long-term outcome at puberty. nameOfConference DOI: doi QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/81440 Wass JAH, Trainer PJ, Korbonits M (2022). Acromegaly. nameOfConference DOI: 10.1093/med/9780198870197.003.0026 QMRO: qmroHref Tseretopoulou X, Ali SR, Bryce J et al. (2022). An International Study of the Association between Local Health Care Resources and Acute Adrenal Insufficiency Events in Children with Congenital Adrenal Hyperplasia. nameOfConference DOI: doi QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84183 Tadokoro-Cuccaro R, Hughes I, Cools M et al. (2022). Gonadal morphology in 46,XY gonadal dysgenesis: I-DSD Registry-based study. nameOfConference DOI: doi QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84179 Marques P, Korbonits M (2022). Pituitary Dysfunction in Systemic Disorders. nameOfConference DOI: 10.1016/B978-0-323-99899-4.00024-X QMRO: qmroHref Canton A, Tinano F, Guasti L et al. (2022). X-Linked Central Precocious Puberty Associated with MECP2 defects. nameOfConference DOI: doi QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/82180 Stelmachowska-Banaś M, Maksymowicz M, Kolasińska-Ćwikła A et al. (2022). Pituitary carcinoma as a rare cause of liver metastases successfully treated with temozolomide.. nameOfConference DOI: 10.20452/pamw.16178 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/76099 Das L, Rai A, Salunke P et al. (2022). Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. nameOfConference DOI: 10.1210/jendso/bvab190 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/76098 Stojanoski S, Boldt HB, Kozic D et al. (publicationYear). Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features. nameOfConference DOI: 10.3389/fonc.2021.739255 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75747 Marques P, Korbonits M (2022). Approach to the Patient With Pseudoacromegaly. nameOfConference DOI: 10.1210/clinem/dgab789 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75748 Marques P, Barry S, Carlsen E et al. (2021). The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. nameOfConference DOI: 10.1111/jne.13052 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75743 Pedraza‐Arevalo S, Ibáñez‐Costa A, Blázquez‐Encinas R et al. (2022). Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST5) in pituitary and pancreatic neuroendocrine tumors. nameOfConference DOI: 10.1002/1878-0261.13107 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/74627 Mistry A, Funge G, Sebastian S et al. (publicationYear). Acromegalic cardiomyopathy in pituitary-specific aryl hydrocarbon receptor interacting protein (Aip) gene knockout animals. nameOfConference DOI: 10.1530/endoabs.77.oc1.3 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75750 Ravi TK, Marwaha R, Malhotra B et al. (publicationYear). Age- gender- and tanner stage-specific reference intervals for serum insulin-like growth factor binding protein 3 (IGFBP-3) and the insulin-like growth factor I (IGF-I) to IGFBP-3 molar ratios in healthy school children of a north indian city. nameOfConference DOI: 10.1530/endoabs.77.p92 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/77543 Begalli F, Komagata T, Suleyman O et al. (publicationYear). Cabergoline treatment in human primary non-functioning pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.77.p212 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75749 Dutta P, Teja KR, Aggarwal A et al. (publicationYear). Generation of normative data on serum insulin-like growth factor I (IGF-I) in healthy school children of a north indian city. nameOfConference DOI: 10.1530/endoabs.77.p223 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/76096 Rai A, Yelamanchi SD, Radotra BD et al. (2021). Hyper-phosphorylation of [beta]-catenin at Serine552 correlates with invasion and predicts recurrence of Non-Functioning Pituitary Tumours (NFPTs). BES2021 DOI: 10.1530/endoabs.77.oc1.2 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/76097 Kaniuka-Jakubowska S, Abeyaratne D, Pal A et al. (publicationYear). Is gigantism different from acromegaly in terms of causes of death, comorbidities and treatment? A preliminary retrospective study of 156 UK giants. nameOfConference DOI: 10.1530/endoabs.77.p81 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/76095 Walker EM, Cha J, Tong X et al. (2021). Sex-biased islet β cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males. nameOfConference DOI: 10.1016/j.celrep.2021.109813 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/74626 Garcia-Rendueles AR, Chenlo M, Oroz-Gonjar F et al. (2021). RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas. nameOfConference DOI: 10.1038/s41388-021-02009-8 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/74628 Cerbone M, Visser J, Bulwer C et al. (2021). Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline. nameOfConference DOI: 10.1016/s2352-4642(21)00088-2 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75741 Hussein Z, Korbonits M, Baldeweg SE et al. (2021). Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma. nameOfConference DOI: 10.1530/edm-21-0003 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75742 Nadhamuni VS, Iacovazzo D, Evanson J et al. (2021). GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. nameOfConference DOI: 10.1530/edm-20-0208 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/73030 Loughrey PB, Craig S, Herron B et al. (2021). Pituitary surgery in northern ireland: A twenty year retrospective population based analysis. nameOfConference DOI: 10.1530/endoabs.73.aep488 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/78007 Bogusławska A, Gilis-Januszewska A, Magdid K et al. (2021). One Fourth of Adult Patients With Acromegaly Have Tall Stature With Similar Frequency in Males And Females. nameOfConference DOI: 10.1210/jendso/bvab048.1319 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/71891 Marques P, de Vries F, Dekkers OM et al. (2021). Serum inflammation-based scores in endocrine tumors.. nameOfConference DOI: 10.1210/clinem/dgab238 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/71608 Koh CH, Khan DZ, Digpal R et al. (2021). P34 Characteristics, diagnosis and management of Cushing’s disease - A systematic review and meta-analysis. nameOfConference DOI: 10.1093/bjsopen/zrab032.033 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/78005 Loughrey PB, Baker G, Herron B et al. (2021). Invasive ACTH-Producing Pituitary Gland Neoplasm Secondary to MSH2 Mutation. nameOfConference DOI: 10.1016/j.cancergen.2021.03.008 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/71524 Bacila I, Freeman N, Daniel E et al. (2021). International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry. nameOfConference DOI: 10.1530/eje-20-1249 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69941 Bogusławska A, Korbonits M (publicationYear). Genetics of Acromegaly and Gigantism. nameOfConference DOI: 10.3390/jcm10071377 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/71521 Das L, Vaiphei K, Rai A et al. (2021). Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. nameOfConference DOI: 10.1530/ec-20-0621 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/70951 Nadaf J, de Kock L, Chong A-S et al. (2021). Molecular characterization of DICER1-mutated pituitary blastoma. nameOfConference DOI: 10.1007/s00401-021-02283-6 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/70632 Ho K, Fleseriu M, Kaiser U et al. (2021). Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. nameOfConference DOI: 10.1210/jendso/bvaa205 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/70634 Dénes J, Korbonits M (2021). The clinical aspects of pituitary tumour genetics. nameOfConference DOI: 10.1007/s12020-021-02633-0 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75744 de Graaf JP, de Vries F, Dirkson A et al. (2021). Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. nameOfConference DOI: 10.1007/s12020-021-02618-z QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75746 Martel-Duguech LM, Jorgensen JOL, Korbonits M et al. (2021). ESE audit on management of Adult Growth Hormone Deficiency in clinical practice.. nameOfConference DOI: 10.1530/eje-20-1180 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69876 Mirczuk SM, Scudder CJ, Read JE et al. (publicationYear). Natriuretic Peptide Expression and Function in GH3 Somatolactotropes and Feline Somatotrope Pituitary Tumours. nameOfConference DOI: 10.3390/ijms22031076 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/70360 Garcia JM, Biller BMK, Korbonits M et al. (2021). Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. nameOfConference DOI: 10.1530/ec-20-0491 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69664 Liu APY, Kelsey MM, Sabbaghian N et al. (2021). Clinical Outcomes and Complications of Pituitary Blastoma. nameOfConference DOI: 10.1210/clinem/dgaa857 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69249 Marques P, de Vries F, Dekkers OM et al. (2021). Pre-operative serum inflammation-based scores in patients with pituitary adenomas. nameOfConference DOI: 10.1007/s11102-020-01112-5 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75745 Shrikrishnapalasuriyar N, Plowman PN, Korbonits M et al. (publicationYear). Endocrine and Neuroendocrine Tumors. nameOfConference DOI: 10.1201/9780429026638-5 QMRO: qmroHref Casar-Borota O, Boldt HB, Engström BE et al. (2021). Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. nameOfConference DOI: 10.1210/clinem/dgaa749 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/68404 (2020). Erratum to: “Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial”. nameOfConference DOI: 10.1210/clinem/dgaa637 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/84184 Carty DM, Harte R, Drummond RS et al. (2020). AIP variant causing familial prolactinoma. nameOfConference DOI: 10.1007/s11102-020-01085-5 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/68531 Ali SR, Bryce J, Haghpanahan H et al. (2021). Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia. nameOfConference DOI: 10.1210/clinem/dgaa694 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/67783 Stütz B, Korbonits M, Kothbauer K et al. (2020). Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly. nameOfConference DOI: 10.1530/edm-20-0119 QMRO: qmroHref Marques P, Barry S, Carlsen E et al. (2020). The role of the tumour microenvironment in the angiogenesis of pituitary tumours. nameOfConference DOI: 10.1007/s12020-020-02478-z QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/68530 Barry S, Korbonits M (2020). Update on the Genetics of Pituitary Tumors. nameOfConference DOI: 10.1016/j.ecl.2020.05.005 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66563 Martel-Duguech L, Screen N, Jorgensen JOL et al. (publicationYear). European Society of Endocrinology audit and multi-country comparison of Adult Growth Hormone Deficiency (AGHD) treatment in clinical practice in Europe and Australia; –how closely are protocols and best practice recommendations followed. nameOfConference DOI: 10.1530/endoabs.70.aep676 QMRO: qmroHref Marques P, Magalhães D, Caimari F et al. (publicationYear). Phenotypic differences between patients with familial pituitary neuroendocrine tumours due to MEN1 or AIP mutations. nameOfConference DOI: 10.1530/endoabs.70.aep600 QMRO: qmroHref Marques P, de VF, van FW et al. (publicationYear). Pre-operative full blood count, C-reactive protein and serum inflammation-based scores may predict aggressive or refractory disease in patients with pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.70.ep295 QMRO: qmroHref Iacovazzo D, Thong LC, Quezado R et al. (publicationYear). The MAFA gene mutation responsible for familial insulinomatosis and diabetes impairs insulin secretion and results in downregulation of critical cell cycle regulators. nameOfConference DOI: 10.1530/endoabs.70.aep281 QMRO: qmroHref Marques P, Barry S, Carlsen E et al. (publicationYear). The role of the tumour microenvironment in pituitary adenoma angiogenesis. nameOfConference DOI: 10.1530/endoabs.70.oc7.2 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/68263 Benjamin LP, Craig S, Herron B et al. (publicationYear). To score or not to score? Is Ki-67 analysis worthwhile in pituitary neuroendocrine tumours?. nameOfConference DOI: 10.1530/endoabs.70.aep671 QMRO: qmroHref Cardenas SMC, El-Kaissi S, Jarad O et al. (2020). Unusual Combination of MEN-1 and the Contiguous Gene Deletion Syndrome of CAH and Ehlers-Danlos Syndrome (CAH-X). nameOfConference DOI: 10.1210/jendso/bvaa077 QMRO: qmroHref Pinto EM, Figueiredo BC, Chen W et al. (2020). XAF1 as a modifier of p53 function and cancer susceptibility. nameOfConference DOI: 10.1126/sciadv.aba3231 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/67958 Marques P, Grossman AB, Korbonits M (2020). The tumour microenvironment of pituitary neuroendocrine tumours. nameOfConference DOI: 10.1016/j.yfrne.2020.100852 QMRO: qmroHref CHA J, WALKER EM, TONG X et al. (2020). 2116-P: MAFA S64F Missense Mutation Causes Islet Beta-Cell Aging and Senescence. nameOfConference DOI: 10.2337/db20-2116-p QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/67968 Dal J, Nielsen EH, Klose M et al. (2020). Phenotypic and genotypic features of a large kindred with a germline AIP variant. nameOfConference DOI: 10.1111/cen.14207 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/65424 Das L, Bhansali A, Ahuja CK et al. (2020). Acquired Ectopic Posterior Pituitary Bright Spot Due to Vasculotoxic Snakebite. nameOfConference DOI: 10.4158/accr-2020-0094 QMRO: qmroHref Nadhamuni VS, Korbonits M (2020). Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. nameOfConference DOI: 10.1210/endrev/bnaa006 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69665 Pernicova I, Kelly S, Ajodha S et al. (2020). Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.. nameOfConference DOI: 10.1016/S2213-8587(20)30021-8 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63260 Marques P, Caimari F, Hernández-Ramírez LC et al. (2020). Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. nameOfConference DOI: 10.1210/clinem/dgaa040 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/65340 Marques P, Stelmachowska-Banas M, Collier D et al. (2020). Pachydermoperiostosis mimicking the acral abnormalities of acromegaly. nameOfConference DOI: 10.1007/s12020-019-02168-5 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63785 Nadhamuni VS, Korbonits M (2020). Inflammatory Mediators Drive Tumorigenesis in Pituitary Adenomas of the PIT1 Lineage. nameOfConference DOI: doi QMRO: qmroHref Iacovazzo D, Chiloiro S, Carlsen E et al. (2020). Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. nameOfConference DOI: 10.1007/s12020-019-02145-y QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/64595 Marques P, Barry S, Carlsen E et al. (2019). Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. nameOfConference DOI: 10.1530/erc-19-0327 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/65369 Nadhamuni VS, Barry S, Korbonits M (publicationYear). Sparsely and densely granulated growth hormone-secreting pituitary tumours (somatotropinomas): from histopathology to epigenomics. nameOfConference DOI: 10.1530/endoabs.67.o37 QMRO: qmroHref Nadhamuni VS, Iacovazzo D, Evanson J et al. (publicationYear). Unusual cause of gigantism - Growth hormone releasing hormone (GHRH)-secreting pancreatic neuroendocrine tumour in a patient with multiple endocrine neoplasia type 1 (MEN1). nameOfConference DOI: 10.1530/endoabs.67.o36 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69404 Kyprianou N, Blackburn J, Tan R et al. (publicationYear). A novel clinical risk score that accurately predicts recurrence of craniopharyngioma - a multicentre cohort study. nameOfConference DOI: 10.1530/endoabs.66.oc4.4 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66580 Bacila I-A, Blankenstein O, Neumann U et al. (publicationYear). Exploring trends in the glucocorticoid and mineralocorticoid treatment of congenital adrenal hyperplasia by analysing data from the I-CAH registry. nameOfConference DOI: 10.1530/endoabs.66.oc1.1 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69518 Marques P, Barry S, Carlsen E et al. (2019). Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. nameOfConference DOI: 10.1186/s40478-019-0830-3 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/61899 Abeyaratne D, Gunatilake S, Joseph N et al. (publicationYear). A rare case of a malignant prolactinoma presenting with skull metastasis after two years of a masked diagnosis. nameOfConference DOI: 10.1530/endoabs.65.p294 QMRO: qmroHref Nadhamuni VS, Barry S, Shaid M et al. (publicationYear). Distinct methylation patterns in sparsely and densely granulated growth hormone-secreting pituitary tumours provide clues to different underlying tumorigenic mechanisms. nameOfConference DOI: 10.1530/endoabs.65.p278 QMRO: qmroHref Raja U, Garcia E, The C et al. (publicationYear). Inhibitory actions of diketopiperazines within the thyroid gland, and their system-wide presence. nameOfConference DOI: 10.1530/endoabs.65.p441 QMRO: qmroHref Mistry A, Solomou A, Vignola ML et al. (publicationYear). Investigating the role of AIP in pituitary tumourigenesis. nameOfConference DOI: 10.1530/endoabs.65.oc2.2 QMRO: qmroHref Al-Jabir H, Barry S, Korbonits M (publicationYear). Review of microarray, RNA sequencing and next-generation sequencing data reveals key pathways involved in pituitary tumorigenesis. nameOfConference DOI: 10.1530/endoabs.65.p298 QMRO: qmroHref Bollington M, Mistry A, Solomou A et al. (publicationYear). Transcriptomic analyses reveal deregulation of focal adhesion pathway in Aip KO mice and AIP mutation positive human tumours. nameOfConference DOI: 10.1530/endoabs.65.op6.2 QMRO: qmroHref Pofi R, Prete A, Thornton-Jones V et al. (2020). Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. nameOfConference DOI: 10.1210/clinem/dgz055 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63898 Dutta A, Pal R, Jain N et al. (2019). Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature. nameOfConference DOI: 10.1210/js.2019-00081 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63901 Manou-Stathopoulou V, Korbonits M, Ackland GL (2019). Redefining the perioperative stress response: a narrative review. nameOfConference DOI: 10.1016/j.bja.2019.08.011 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/62840 Gan H-W, Morillon P, Albanese A et al. (2019). National United Kingdom evidence- and consensus-based guidelines for the investigation, treatment and long-term follow-up of paediatric craniopharyngioma. 47th Meeting of the British Society for Paediatric Endocrinology and Diabetes DOI: 10.1530/endoabs.66.OC2.1 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69569 Ribeiro-Oliveira A, Korbonits M, V Freire C (2019). Assessment of Cardiavascular Changes following Trans-sphenoidal Surgery in Acromegalic Patients. nameOfConference DOI: 10.4103/0028-3886.266294 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63835 Dutta P, Reddy KS, Rai A et al. (2019). Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child. nameOfConference DOI: 10.1210/jc.2019-00432 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/58509 Marques P, Barry S, Carlsen E et al. (publicationYear). Pituitary tumour-derived chemokines modulate immune cell infiltrates in the tumour microenvironment leading to aggressive phenotype. nameOfConference DOI: 10.1530/endoabs.63.oc13.3 QMRO: qmroHref Stojanovic M, Wu Z, Stiles C et al. (publicationYear). Serum aryl hydrocarbon receptor-interacting protein (AIP) levels are independent of serum GH levels both at baseline and in dynamic tests of GH stimulation and suppression. nameOfConference DOI: 10.1530/endoabs.63.p236 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66863 Urmanova Y, Grossman A, Khalimova Z et al. (publicationYear). Some risk factors of re-growth of non-functional pituitary adenomas in patients with growth hormone deficiency. nameOfConference DOI: 10.1530/endoabs.63.p237 QMRO: qmroHref Khalimova Z, Grossman A, Levy M et al. (publicationYear). The frequency of subclinical cushing's syndrome in women with polycystic ovaries syndrome. nameOfConference DOI: 10.1530/endoabs.63.ep85 QMRO: qmroHref Jawiarczyk-Przybyłowska A, Wojtczak B, Whitworth J et al. (2019). Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. nameOfConference DOI: 10.5603/ep.a2019.0005 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/59082 Sun D, Stopka-Farooqui U, Barry S et al. (2019). Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. nameOfConference DOI: 10.1016/j.celrep.2019.04.014 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/57415 Marques P, Barry S, Carlsen E et al. (2019). MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?. nameOfConference DOI: 10.1210/js.2019-mon-460 QMRO: qmroHref Marques P, Barry S, Carlsen E et al. (2019). MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on Macrophages. nameOfConference DOI: 10.1210/js.2019-mon-462 QMRO: qmroHref Garcia J, Biller BMK, Korbonits M et al. (2019). OR16-1 Best of The Journal of Clinical Endocrinology & Metabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency. nameOfConference DOI: 10.1210/js.2019-or16-1 QMRO: qmroHref Garcia J, Biller B, Korbonits M et al. (2019). OR32-4 Diagnostic Performance of Macimorelin vs the Insulin Tolerance Test (ITT) in 140 Patients at Varying Growth Hormone (GH) Cutpoints: A Post Hoc Analysis. nameOfConference DOI: 10.1210/js.2019-or32-4 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66816 Garcia J, Biller BM, Korbonits M et al. (2019). SAT-428 Effect of Age, Body Mass Index, and Sex on the Performance of Macimorelin for the Diagnosis of Adult Growth Hormone Deficiency: A Post Hoc Analysis. nameOfConference DOI: 10.1210/js.2019-sat-428 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66868 Marques P, Caimari F, Hernández-Ramírez L et al. (2019). SAT-462 AIP Mutation-Positive Patients with Somatotropinomas End up Taller and Requiring Radiotherapy More Often Compared to AIP Mutation-Negative Patients: Data from 784 Familial and Young-Onset Cases. nameOfConference DOI: 10.1210/js.2019-sat-462 QMRO: qmroHref BARRY S, Sun D, Stopka-Farooqui U et al. (2019). SAT-LB056 Is AIP a Tumor Suppressor or an Oncogene? AIP as a Novel Regulator of the Oncogene BCL6 in Diffuse Large B Cell Lymphoma. nameOfConference DOI: 10.1210/js.2019-sat-lb056 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66869 Barry S, Carlsen E, Marques P et al. (2019). Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. nameOfConference DOI: 10.1038/s41388-019-0779-5 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/57414 Stojanovic M, Wu Z, Stiles CE et al. (2019). Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion. nameOfConference DOI: 10.1530/ec-19-0082 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/57618 Pepe S, Korbonits M, Iacovazzo D (2019). Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. nameOfConference DOI: 10.1530/joe-18-0446 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/56073 Castinetti F, Waguespack SG, Machens A et al. (2019). Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. nameOfConference DOI: 10.1016/s2213-8587(18)30336-x QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58051 Hebenstreit D, Ahmed F, Springer A et al. (2019). Contemporary surgical approach in CAH 46XX-Results from the I-DSD/I-CAH Registries. nameOfConference DOI: doi QMRO: qmroHref Ali S, Daniel E, Bryce J et al. (2019). Development Of An International Benchmark For Sick Day Episodes As A Core Clinical Outcome In People With Congenital Adrenal Hyperplasia. nameOfConference DOI: doi QMRO: qmroHref Loughrey PB, Korbonits M (2019). Genetics of Pituitary Tumours. nameOfConference DOI: 10.1007/978-3-030-25905-1_10 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63790 Bacila I-A, Blankenstein O, Neumann U et al. (2019). Global Practice of Glucocorticoid and Mineralocorticoid Treatment in Children and Adults with Congenital Adrenal Hyperplasia - Insights from the I-CAH Registry. nameOfConference DOI: doi QMRO: qmroHref Neumann U, van der Linde A, Krone R et al. (2019). Influence of salt supplementation on drug therapy in children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency aged 0-3 years: Update on a retrospective multicentre analysis using the I-CAH registry. nameOfConference DOI: doi QMRO: qmroHref Bizzi MF, Bolger GB, Korbonits M et al. (2019). Phosphodiesterases and cAMP pathway in pituitary diseases. nameOfConference DOI: 10.3389/fendo.2019.00141 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63723 Ali SR, Bryce J, Cools M et al. (2019). The current landscape of European registries for rare endocrine conditions. nameOfConference DOI: 10.1530/eje-18-0861 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/56229 Yelamanchi SD, Tyagi A, Mohanty V et al. (2018). Proteomic Analysis of the Human Anterior Pituitary Gland. nameOfConference DOI: 10.1089/omi.2018.0160 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/56784 Marques P, Korbonits M (2019). Pseudoacromegaly. nameOfConference DOI: 10.1016/j.yfrne.2018.11.001 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/55057 Lim CT, Bertalan R, Davies C et al. (publicationYear). A novel case of primary hypogonadism in female associated with Loeys-Dietz syndrome type 5. nameOfConference DOI: 10.1530/endoabs.59.cc4 QMRO: qmroHref Yang ZJ, Lillina VM, Collier D et al. (publicationYear). Identifying disease causing variants in aryl hydrocarbon receptor-interacting protein (AIP) variants and their significance on the clinical phenotypes. nameOfConference DOI: 10.1530/endoabs.59.p127 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66758 Al JH, Barry S, Korbonits M (publicationYear). Overexpression of SKAP2 in familial AIP mutation negative somatotrophinomas. nameOfConference DOI: 10.1530/endoabs.59.oc2.6 QMRO: qmroHref Scudder CJ, Mirczuk SM, Richardson KM et al. (2019). Pituitary pathology and gene expression in acromegalic cats. nameOfConference DOI: 10.1210/js.2018-00226 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63747 Marques P, Collier D, Barkan A et al. (2018). Coexisting pituitary and non‐pituitary gigantism in the same family. nameOfConference DOI: 10.1111/cen.13852 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/49843 Günther T, Tulipano G, Dournaud P et al. (2018). International union of basic and clinical pharmacology. CV. somatostatin receptors: Structure, function, ligands, and new nomenclature. nameOfConference DOI: 10.1124/pr.117.015388 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/49064 Subasinghe CJ, Somasundaram N, Sivatharshya P et al. (2018). Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN‐1 Syndrome. nameOfConference DOI: 10.1155/2018/2875074 QMRO: qmroHref Maher M, Roncaroli F, Mendoza N et al. (publicationYear). A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma. nameOfConference DOI: 10.1530/edm-18-0078 QMRO: qmroHref Drummond J, Roncaroli F, Grossman AB et al. (2019). Clinical and Pathological Aspects of Silent Pituitary Adenomas. nameOfConference DOI: 10.1210/jc.2018-00688 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/63834 Caimari F, Kumar AV, Kurzawinski T et al. (2018). A novel DICER1 mutation in familial multinodular goitre. nameOfConference DOI: 10.1111/cen.13613 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/58627 Németh K, Szücs N, Czirják S et al. (2018). Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas. nameOfConference DOI: 10.18632/oncotarget.25650 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43423 Gan H-W, Aquilina K, Morillon P et al. (2018). CRAN-08. NATIONAL UK GUIDELINES FOR THE INVESTIGATION, TREATMENT AND LONG-TERM FOLLOW-UP OF PAEDIATRIC CRANIOPHARYNGIOMA. nameOfConference DOI: 10.1093/neuonc/noy059.045 QMRO: qmroHref Dastamani A, Bulwer C, Korbonits M et al. (2018). CRAN-28. A SINGLE CENTER EXPERIENCE OF MANAGING A SERIES OF CHILDHOOD MACROPROLACTINOMAS. nameOfConference DOI: 10.1093/neuonc/noy059.064 QMRO: qmroHref Blair J, Korbonits M, Ronaldson A et al. (2018). CRAN-40. A NATIONAL UK GUIDELINE FOR MANAGING PITUITARY ADENOMAS IN CHILDREN AND YOUNG PEOPLE UNDER 19 YEARS DEVELOPED ACCORDING TO THE AGREE II FRAMEWORK. nameOfConference DOI: 10.1093/neuonc/noy059.075 QMRO: qmroHref Cerbone M, Visser J, Bulwer C et al. (2018). GERM-22. DECISION-MAKING MANAGEMENT GUIDELINE FOR CHILDREN AND YOUNG PEOPLE UP TO 19 YEARS (CYP) PRESENTING WITH IDIOPATHIC PITUITARY STALK THICKENING (iTPS) AND/OR IDIOPATHIC CENTRAL DIABETES INSIPIDUS (iCDI). nameOfConference DOI: 10.1093/neuonc/noy059.269 QMRO: qmroHref Hérincs M, Young K, Korbonits M (2018). Physiology of the pituitary gland. nameOfConference DOI: doi QMRO: qmroHref Garcia JM, Biller BMK, Korbonits M et al. (2018). Macimorelin as a Diagnostic Test for Adult GH Deficiency. nameOfConference DOI: 10.1210/jc.2018-00665 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/44684 Ali SR, Bryce J, Cools M et al. (publicationYear). Awareness & participation in rare disease registries within the European reference network on rare endocrine conditions (Endo-ERN). nameOfConference DOI: 10.1530/endoabs.56.p677 QMRO: qmroHref Pedraza-Arevalo S, Ibanez-Costa A, Vazquez-Borrego MC et al. (publicationYear). Epigenetic and post-transcriptional regulation of the SSTR5 gene in somatotropinomas. nameOfConference DOI: 10.1530/endoabs.56.gp201 QMRO: qmroHref Ibanez-Costa A, Leton R, Rivero-Cortes E et al. (publicationYear). Prominent expression of MAX and MEG3, despite lack of mutations in MAX, suggest a potential role for 14q genes in pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.56.gp199 QMRO: qmroHref Mitravela V-I, Glynn N, Waterhouse M et al. (publicationYear). Treatment strategies in medullary thyroid carcinoma - outcome following initial surgery with a curative, debulking or prophylactic intent. nameOfConference DOI: 10.1530/endoabs.56.p1160 QMRO: qmroHref Bizzi MF, Pinheiro SVB, Bolger GB et al. (publicationYear). Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas. nameOfConference DOI: 10.1016/j.mce.2018.04.014 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/40163 Prete FP, Abdel-Aziz T, Morkane C et al. (2018). Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2. nameOfConference DOI: 10.1002/bjs.10856 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/53286 Lim CT, Korbonits M (2018). UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.. nameOfConference DOI: 10.4158/EP-2018-0034 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/41935 Aflorei ED, Klapholz B, Chen C et al. (2018). In vivo bioassay to test the pathogenicity of missense human AIP variants. nameOfConference DOI: 10.1136/jmedgenet-2017-105191 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/45365 (2018). Preliminaries. nameOfConference DOI: 10.1159/000485993 QMRO: qmroHref Marques P, Barry S, Ronaldson A et al. (2018). Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.. nameOfConference DOI: 10.1155/2018/8581626 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/50124 Stiles CE, Thuraisingham R, Bockenhauer D et al. (2018). De novo HNF1 homeobox B mutation as a cause for chronic, treatment-resistant hypomagnesaemia.. nameOfConference DOI: 10.1530/EDM-17-0120 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/36267 Apps JR, Carreno G, Gonzalez-Meljem JM et al. (2018). Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. nameOfConference DOI: 10.1007/s00401-018-1830-2 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/36231 Cerbone M, Visser J, Bulwer C et al. (2018). G356 Decision making management guideline for patients (<19 y) with idiopathic thickened pituitary stalk and/or idiopathic central diabetes insipidus. British Society for Haematology and Children’s Cancer and Leukaemia Group DOI: 10.1136/archdischild-2018-rcpch.346 QMRO: qmroHref Caimari F, Hernández-Ramírez LC, Dang MN et al. (2018). Risk category system to identify pituitary adenoma patients with AIP mutations. nameOfConference DOI: 10.1136/jmedgenet-2017-104957 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/38083 Imran SA, Aldahmani KA, Penney L et al. (2018). Unusual AIP mutation and phenocopy in the family of a young patient with acromegalic gigantism.. nameOfConference DOI: 10.1530/EDM-17-0092 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/61579 Iacovazzo D, Flanagan SE, Walker E et al. (2018). MAFA missense mutation causes familial insulinomatosis and diabetes mellitus.. nameOfConference DOI: 10.1073/pnas.1712262115 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/32132 McCormack A, Dekkers OM, Petersenn S et al. (2018). Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. nameOfConference DOI: 10.1530/eje-17-0933 QMRO: qmroHref Marques P, Spencer R, Morrison PJ et al. (2018). Cantú syndrome with coexisting familial pituitary adenoma. nameOfConference DOI: 10.1007/s12020-017-1497-9 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/32045 Hernández-Ramírez LC, Morgan RML, Barry S et al. (2018). Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. nameOfConference DOI: 10.18632/oncotarget.24183 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/36452 Freund K, Malhorta N, Dastamani A et al. (2018). A 7-Year Update Report of a National, Interdisciplinary Endeavour to Improve Outcomes for Children and Young People Under 19 Years of Age with Hypothalamic Pituitary Axis Tumours (HPAT) Using Multi-Site Video Conferencing. nameOfConference DOI: doi QMRO: qmroHref Blair J, Korbonits M, Ronaldson A et al. (2018). A NATIONAL UK GUIDELINE FOR MANAGING PITUITARY ADENOMAS IN CHILDREN AND YOUNG PEOPLE UNDER 19 YEARS DEVELOPED ACCORDING TO THE AGREE II FRAMEWORK. nameOfConference DOI: doi QMRO: qmroHref Blair J, Korbonits M, Ronaldson A et al. (2018). A National UK Guideline for Managing Pituitary Adenomas in Children and Young People Under 19 Years Developed According to The AGREE II Framework. nameOfConference DOI: doi QMRO: qmroHref Dastamani A, Bulwer C, Korbonits M et al. (2018). A SINGLE CENTER EXPERIENCE OF MANAGING A SERIES OF CHILDHOOD MACROPROLACTINOMAS. nameOfConference DOI: doi QMRO: qmroHref Dastamani A, Bulwer C, Ederies A et al. (2018). A Single Centre Experience of Managing a Series of Childhood Macro/Giant-prolactinoma. nameOfConference DOI: doi QMRO: qmroHref Korbonits M (2018). All you need to know about the genetics of pituitary adenomas. nameOfConference DOI: doi QMRO: qmroHref Anandhakrishnan A, Korbonits M (2018). Chapter 3 Glucagon-Like Peptide 1 and Human Obesity. nameOfConference DOI: 10.1016/b978-0-323-48559-3.00003-8 QMRO: qmroHref Cerbone M, Visser J, Bulwer C et al. (2018). DECISION-MAKING MANAGEMENT GUIDELINE FOR CHILDREN AND YOUNG PEOPLE UP TO 19 YEARS (CYP) PRESENTING WITH IDIOPATHIC PITUITARY STALK THICKENING (ITPS) AND/OR IDIOPATHIC CENTRAL DIABETES INSIPIDUS (ICDI). nameOfConference DOI: doi QMRO: qmroHref Dastamani A, Ederies A, Aquilina K et al. (2018). Invasive Macroprolactinoma with Cabergoline Induced Cerebrospinal Fluid Rhinorrhoea in Childhood. nameOfConference DOI: doi QMRO: qmroHref Popovic V, Korbonits M (2018). Metabolic Syndrome Consequent to Endocrine Disorders Preface. nameOfConference DOI: doi QMRO: qmroHref Ferraù F, Korbonits M (2018). Metabolic syndrome in cushing's syndrome patients. nameOfConference DOI: 10.1159/000486002 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/51504 Gan H-W, Aquilina K, Morillon P et al. (2018). NATIONAL UK GUIDELINES FOR THE INVESTIGATION, TREATMENT AND LONG-TERM FOLLOW-UP OF PAEDIATRIC CRANIOPHARYNGIOMA. nameOfConference DOI: doi QMRO: qmroHref Cerbone M, Bulwer C, Ederies A et al. (2018). National Multidisciplinary Decision-Making Guideline for Children and Young People (Idiopathic Thickened Pituitary Stalk And/or Idiopathic Central Diabetes Insipidus. nameOfConference DOI: doi QMRO: qmroHref Popovic V, Korbonits M (2018). Preface. nameOfConference DOI: 10.1159/000485993 QMRO: qmroHref Araujo PB, Kasuki L, de Azeredo Lima CH et al. (2017). AIP mutations in brazilian patients with sporadic pituitary adenomas: A single-center evaluation. nameOfConference DOI: 10.1530/EC-17-0237 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/31805 Ribeiro-Oliveira A, Korbonits M, Freire C (2017). Echocardiographic improvements following transsphenoidal surgery for acromegaly. nameOfConference DOI: 10.4103/0028-3886.217983 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/32151 Iyer D, Kershaw M, Karavitaki N et al. (publicationYear). Growth hormone secreting adenomas and the challenges of treatment in children. nameOfConference DOI: 10.1530/endoabs.51.p045 QMRO: qmroHref Barry S, Solomou A, Vignola L et al. (publicationYear). A comprehensive analysis of the AIP mutation positive pituitary tumour microenvironment: role of stromal cells and the pro-inflammatory cytokine network. nameOfConference DOI: 10.1530/endoabs.50.p274 QMRO: qmroHref Iacovazzo D, Kumar A, Abbs S et al. (publicationYear). A novel variant in the androgen receptor gene causing familial mild androgen insensitivity syndrome. nameOfConference DOI: 10.1530/endoabs.50.cc03 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66720 Solomou A, Herincs M, Roncaroli F et al. (publicationYear). Investigating the role of AIP in mouse pituitary adenoma formation. nameOfConference DOI: 10.1530/endoabs.50.oc1.6 QMRO: qmroHref Marques P, Ronaldson A, Spencer R et al. (publicationYear). Novel ABCC9 mutation with Cantu syndrome-associated phenotype of hypertrichosis with acromegaloid facial features (HAFF) with coexisting familial pituitary adenoma. nameOfConference DOI: 10.1530/endoabs.50.cc01 QMRO: qmroHref Pérez-Rivas LG, Theodoropoulou M, Puar TH et al. (2018). Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor. nameOfConference DOI: 10.1530/eje-17-0634 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/32332 Koehler VF, Jungheim K, Groß U et al. (2017). Novel Germline p.Gly42Val MEN1 Mutation in a Family with Multiple Endocrine Neoplasia Type 1 - Excellent Response of Prolactinoma to Cabergoline.. nameOfConference DOI: doi QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/58604 Ibáñez-Costa A, Korbonits M (2017). AIP and the somatostatin system in pituitary tumours. nameOfConference DOI: 10.1530/JOE-17-0254 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/34264 Ibáñez-Costa A, Korbonits M (2017). AIP and the somatostatin system in pituitary tumours.. nameOfConference DOI: 10.1530/JOE-17-0254 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/36433 Kiefer FW, Winhofer Y, Iacovazzo D et al. (2017). PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex.. nameOfConference DOI: 10.1530/EJE-17-0227 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/58049 Stelmachowska-Banaś M, Zgliczyński W, Tutka P et al. (2017). Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion. nameOfConference DOI: 10.1210/jc.2017-01045 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/34523 Dahlqvist P, Spencer R, Marques P et al. (2017). Pseudoacromegaly: A differential diagnostic problem for acromegaly with a genetic solution. nameOfConference DOI: 10.1210/js.2017-00164 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/65015 Salvatori R, Radian S, Diekmann Y et al. (2017). In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism.. nameOfConference DOI: 10.1530/EJE-17-0293 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/25046 Marques P, Korbonits M (2017). Genetic Aspects of Pituitary Adenomas.. nameOfConference DOI: 10.1016/j.ecl.2017.01.004 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/22763 Miljic D, Pekic S, Doknic M et al. (publicationYear). Changes in pituitary tumour biology and behaviour in FIPA patient with GH secreting aggressive pituitary macro adenoma. nameOfConference DOI: 10.1530/endoabs.49.ep954 QMRO: qmroHref Marques P, Dang M, Ogilvie A et al. (publicationYear). Long-term follow-up of a family with a large AIP gene deletion: variable phenotypes and challenges in the management. nameOfConference DOI: 10.1530/endoabs.49.gp195 QMRO: qmroHref Perez-Rivas LG, Theodoropoulou M, Puar TH et al. (publicationYear). Somatic mutations in USP8 are frequent events in pituitary tumors causing Nelson's syndrome. nameOfConference DOI: 10.1530/endoabs.49.gp160 QMRO: qmroHref Shaid M, Korbonits M (2017). Genetics of pituitary adenomas. nameOfConference DOI: 10.4103/neuroindia.NI_330_17 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/24811 Doleschall M, Luczay A, Koncz K et al. (2017). A unique haplotype of RCCX copy number variation: from the clinics of congenital adrenal hyperplasia to evolutionary genetics.. nameOfConference DOI: 10.1038/ejhg.2017.38 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/24509 Asa SL, Casar-Borota O, Chanson P et al. (2017). From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. nameOfConference DOI: 10.1530/erc-17-0004 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/23610 Bulwer C, Conn R, Shankar A et al. (2017). Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. nameOfConference DOI: 10.1111/cen.13339 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/23084 Tufton N, Roncaroli F, Hadjudemetriou I et al. (publicationYear). Metastatic pituitary carcinoma in an SDHB mutation positive patient. nameOfConference DOI: 10.1530/endoabs.48.o2 QMRO: qmroHref Iacovazzo D, Hernández-Ramírez LC, Korbonits M (2017). Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. nameOfConference DOI: 10.1080/17446651.2017.1306439 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/22683 Tufton N, Roncaroli F, Hadjidemetriou I et al. (2017). Pituitary Carcinoma in a Patient with an SDHB Mutation.. nameOfConference DOI: 10.1007/s12022-017-9474-7 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/57934 Thomas JDJ, Dattani A, Zemrak F et al. (2017). Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. nameOfConference DOI: 10.1055/s-0042-123710 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/21839 Mitra MT, Jönsson P, Åkerblad AC et al. (2017). Social, educational and vocational outcomes in patients with childhood-onset and young-adult-onset growth hormone deficiency. nameOfConference DOI: 10.1111/cen.13291 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/22060 Roncaroli F, Iacovazzo D, Rodd C et al. (2017). Distinct pathological features of pituitary adenomas in patients with X-linked acrogigantism (XLAG). 118th Meeting of the British-Neuropathological-Society DOI: doi QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/59235 Roncaroli F, Tufton N, Hadjidemetriou I et al. (2017). Pituitary carcinoma in a patient with germline Succinate Dehydrogenase B mutation. 118th Meeting of the British-Neuropathological-Society DOI: 10.1111/nan.12383 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/59319 Gadelha MR, Kasuki L, Korbonits M (2017). The genetic background of acromegaly.. nameOfConference DOI: 10.1007/s11102-017-0789-7 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/21959 Karimova MM, Halimova ZY, Urmanova YM et al. (2017). Pachydermoperiostosis masquerading as acromegaly. nameOfConference DOI: 10.1210/js.2016-1084 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/64967 Seelig E, Meyer S, Timper K et al. (2017). Metformin prevents metabolic side effects during systemic glucocorticoid treatment.. nameOfConference DOI: 10.1530/EJE-16-0653 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/21739 Kyriakakis N, Trouillas J, Dang MN et al. (2017). Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour. nameOfConference DOI: 10.1530/edm-16-0104 QMRO: qmroHref Visser J, Cerbone M, Bulwer C et al. (2017). Diagnostic and Management Guideline for Patients (<19Y) with a Thickened Pituitary Stalk and/or Central Diabetes Insipidus. nameOfConference DOI: doi QMRO: qmroHref Costa MM, Korbonits M (2017). Genetic Causes of Familial Pituitary Tumors. nameOfConference DOI: 10.1016/b978-0-12-801238-3.64199-5 QMRO: qmroHref Marques P, Pereira C, Korbonits M (2017). Langerhans cell histiocytosis: Pathophysiology, diagnosis, and management. nameOfConference DOI: doi QMRO: qmroHref Gan H-W, Albanese A, Morillon P et al. (2017). NATIONAL UK GUIDELINES FOR THE INVESTIGATION, TREATMENT AND LONG-TERM FOLLOW-UP OF PAEDIATRIC CRANIOPHARYNGIOMA. nameOfConference DOI: doi QMRO: qmroHref Butz H, Németh K, Czenke D et al. (2017). Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas. nameOfConference DOI: 10.1007/s12253-016-0163-5 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/18822 Anandhakrishnan A, Korbonits M (2016). Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. nameOfConference DOI: 10.4239/wjd.v7.i20.572 QMRO: qmroHref Tufton N, Shapiro L, Srirangalingam U et al. (2017). Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. nameOfConference DOI: 10.1111/cen.13246 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/25948 Afghan WK, Iacovazzo D, Alevizaki M et al. (publicationYear). ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma. nameOfConference DOI: 10.1530/endoabs.44.p249 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66733 Datta S, Dang MN, Baborie A et al. (publicationYear). Glioma in an AIP mutation carrier patient. nameOfConference DOI: 10.1530/endoabs.44.ep80 QMRO: qmroHref Young K, Orban N, Clarke P et al. (publicationYear). Olfactory neuroblastoma: a multi centre clinical and pathological review. nameOfConference DOI: 10.1530/endoabs.44.p165 QMRO: qmroHref Mothojakan NB, Ferrau F, Dang MN et al. (publicationYear). Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma. nameOfConference DOI: 10.1530/endoabs.44.p167 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/66855 Spencer R, Dahlqvist P, Dang MN et al. (publicationYear). Pseudoacromegaly - a differential diagnostic problem for acromegaly. nameOfConference DOI: 10.1530/endoabs.44.ep79 QMRO: qmroHref Shaid M, Barry S, Gadaleta E et al. (publicationYear). The clinical, pathological and molecular differences between sparsely and densely granulated somatotroph adenomas. nameOfConference DOI: 10.1530/endoabs.44.p162 QMRO: qmroHref Barry S, Carlsen E, Gadaleta E et al. (publicationYear). The role of the microenvironment in the invasive phenotype of familial pituitary tumours. nameOfConference DOI: 10.1530/endoabs.44.p156 QMRO: qmroHref Caimari F, Korbonits M (2016). Novel genetic causes of pituitary adenomas. nameOfConference DOI: 10.1158/1078-0432.CCR-16-0452 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/17893 (2016). Erratum. nameOfConference DOI: 10.1210/jc.2016-4113 QMRO: qmroHref Radian S, Diekmann Y, Gabrovska P et al. (2017). Increased Population Risk of AIP‐Related Acromegaly and Gigantism in Ireland. nameOfConference DOI: 10.1002/humu.23121 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/17888 Iacovazzo D, Korbonits M (2016). Gigantism: X-linked acrogigantism and GPR101 mutations.. nameOfConference DOI: 10.1016/j.ghir.2016.09.007 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/18720 Thomas JDJ, Dattani A, Zemrak F et al. (publicationYear). Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. nameOfConference DOI: 10.1007/s12020-016-1067-6 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/15985 Yelamanchi SD, Solanki HS, Radhakrishnan A et al. (publicationYear). Signaling network map of the aryl hydrocarbon receptor. nameOfConference DOI: 10.1007/s12079-016-0341-y QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/15021 Srirangalingam U, Banerjee A, Patki P et al. (2017). Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas. nameOfConference DOI: 10.1016/j.clgc.2016.06.006 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/23044 Bolger GB, Bizzi MF, Pinheiro SV et al. (2016). cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors. nameOfConference DOI: 10.1530/ERC-15-0205 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/15022 Hernández-Ramírez LC, Martucci F, Morgan RML et al. (2016). Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations. nameOfConference DOI: 10.1210/jc.2016-1307 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/17773 Iacovazzo D, Caswell R, Bunce B et al. (2016). Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. nameOfConference DOI: 10.1186/s40478-016-0328-1 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/23056 Stojanovic M, Aflorei ED, McGonnell I et al. (publicationYear). AIP inactivation leads to pituitary enlargement in the Zebrafish embryo model. nameOfConference DOI: 10.1530/endoabs.41.ep854 QMRO: qmroHref Aflorei ED, Klapholz B, Moderau N et al. (publicationYear). The Drosophila AIP orthologue is essential for actin cytoskeleton stabilisation and cell adhesion. nameOfConference DOI: 10.1530/endoabs.41.oc5.1 QMRO: qmroHref Ferreira VM, Marcelino M, Piechnik SK et al. (2016). Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. nameOfConference DOI: 10.1016/j.jacc.2016.03.543 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/14450 Rodd C, Millette M, Iacovazzo D et al. (2016). Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management. nameOfConference DOI: 10.1210/jc.2015-4366 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/13770 Ramírez-Rentería C, Hernández-Ramírez LC, Portocarrero-Ortiz L et al. (2016). AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. nameOfConference DOI: 10.1007/s12020-016-0930-9 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/15024 Syro LV, Rotondo F, Kovacs K et al. (2016). Clinicopathologic features of familial pituitary adenomas. nameOfConference DOI: 10.1016/j.mpdhp.2016.02.004 QMRO: qmroHref Vujovic S, Vujosevic S, Kavaric S et al. (2016). Cancerous leptomeningitis and familial congenital hypopituitarism. nameOfConference DOI: 10.1007/s12020-016-0868-y QMRO: qmroHref Hernandez-Ramirez LC, Morgan RML, Chrisostomos Prodromou C et al. (2016). A Proteomic Approach to Unveil the Pituitary-Specific Tumour Suppressor Mechanisms of AIP. Endocr. Rev DOI: doi QMRO: qmroHref Dutta P, Korbonits M, Sachdeva N et al. (2016). Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?. nameOfConference DOI: 10.4103/0028-3886.177622 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/15026 Portocarrero-Ortiz L, Martinez-Gigena MP, Alcocer-Barradas V et al. (2016). Clinical Case : Gigantism Due to AIP Mutation in a 9 Years-Old Identical Twin. Endocr. Rev DOI: doi QMRO: qmroHref Caimari F, Dang MN, Hernandez-Ramirez LC et al. (2016). Clinical Characteristics Predicting AIP Mutation Status in Pituitary Adenoma Patients. Endocr. Rev DOI: doi QMRO: qmroHref Ilie I, Korbonits M (2016). Clinical Features of Acromegaly☆. nameOfConference DOI: 10.1016/b978-0-12-801238-3.95964-6 QMRO: qmroHref Ilie I, Korbonits M (2016). Diagnosis of Acromegaly. nameOfConference DOI: 10.1016/b978-0-12-801238-3.95965-8 QMRO: qmroHref Korbonits M, Dutta P, Reddy KS et al. (2016). Exome Sequencing Reveals Double Hit By AIP Gene Mutation and Copy Loss of Chromosome 11 but Negative X-LAG in a Pituitary Adenoma of a 4 Yrs Child with Gigantism Treated with Multimodal Therapy. Endocr. Rev DOI: doi QMRO: qmroHref Scudder CJ, Mirczuk SM, Richardson KM et al. (2016). Feline Hypersomatotropism As a Spontaneous Animal Model of Acromegaly: Molecular Analyses of Somatostatin and Dopamine Receptor Expression in GH-Secreting Adenomas in the Cat (Felis catus). Endocr. Rev DOI: doi QMRO: qmroHref Iacovazzo D, Kapur S, Bunce B et al. (2016). GPR101 Variants in Acromegaly: Results from a Large Series of Patients. Endocr. Rev DOI: doi QMRO: qmroHref Dworakowska D, Paulina Szyszka P, Diaz-Cano SJ et al. (2016). Metformin Alters an Anti-Proliferative Effect of Mitotane in a Human Adrenocortical Cancer (H295R) Cell Line: Preliminary Results. Endocr. Rev DOI: 10.1530/endoabs.44.p131 QMRO: qmroHref Koehler VF, Jungheim K, Gross U et al. (2016). Novel germline p.Gly42Val MEN1 mutation in a family with multiple endocrine neoplasia type 1. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Millette M, Iacovazzo D et al. (2016). Somatic Xq26.3 Microduplication Causing X-Linked Acrogigantism (X-LAG). Endocr. Rev DOI: doi QMRO: qmroHref Iacovazzo D, Jose S, Bunce B et al. (2016). X-Linked Acrogigantism (X-LAG): Novel Histopathological and Clinical Characterisation. Endocr. Rev DOI: doi QMRO: qmroHref Strasburger CJ, Karavitaki N, Störmann S et al. (2016). Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. nameOfConference DOI: 10.1530/eje-15-1042 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12718 Nölting S, Maurer J, Spöttl G et al. (publicationYear). Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. nameOfConference DOI: 10.1371/journal.pone.0143830 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12719 Iacovazzo D, Carlsen E, Lugli F et al. (2016). Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. nameOfConference DOI: 10.1530/eje-15-0832 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/45784 Raman NAK, Michaelidou M, Dimitrakopoulou E et al. (publicationYear). Achieving a consensus on managing idiopathic thickening of the pituitary stalk through a national multidisciplinary forum, meeting virtually. nameOfConference DOI: 10.1530/endoabs.39.ep108 QMRO: qmroHref Coxson E, Barton J, Dang M et al. (publicationYear). Childhood somatotroph pituitary adenomas due to aryl hydrocarbon receptor interacting protein ( AIP ) gene mutations. nameOfConference DOI: 10.1530/endoabs.39.ep105 QMRO: qmroHref Coxson E, Iacovazzo D, Bunce B et al. (publicationYear). Pegvisomant treatment for X-linked acrogigantism syndrome. nameOfConference DOI: 10.1530/endoabs.39.oc5.10 QMRO: qmroHref Agustsson TT, Baldvinsdottir T, Jonasson JG et al. (2015). The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. nameOfConference DOI: 10.1530/eje-15-0189 QMRO: qmroHref Gupta P, Rai A, Sachdeva N et al. (publicationYear). In vitro effects of Imatinib on somatotrophinoma cell line. nameOfConference DOI: 10.1530/endoabs.38.p305 QMRO: qmroHref Stiles C, Barry S, Gadaleta E et al. (publicationYear). Investigation of the invasive phenotype of AIP-mutated pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.38.p301 QMRO: qmroHref Young K, Alusi G, Korbonits M (publicationYear). Novel targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma. nameOfConference DOI: 10.1530/endoabs.38.p153 QMRO: qmroHref Barry S, Carlsen E, Saleh JA et al. (publicationYear). Potential molecular mechanism of AIP-mediated cellular invasion. nameOfConference DOI: 10.1530/endoabs.38.fp11 QMRO: qmroHref Mothojakan NB, Stiles CE, Barry S et al. (publicationYear). Silencing of aryl hydrocarbon receptor protein (AIP) up-regulates the small Rho GTPase, CDC42. nameOfConference DOI: 10.1530/endoabs.38.p307 QMRO: qmroHref Caimari F, Dang MN, Gabrovska P et al. (publicationYear). The burden of AIP mutations in pituitary adenoma patients from the UK. nameOfConference DOI: 10.1530/endoabs.38.p311 QMRO: qmroHref de OAM, Soare DS, Radian S et al. (publicationYear). The effect of AIP on AHR transcriptional activity: implications for AIP mutations pathogenicity. nameOfConference DOI: 10.1530/endoabs.38.p300 QMRO: qmroHref Radian S, Diekmann Y, Gabrovska P et al. (publicationYear). The founder R304* AIP mutation is prevalent in Irish acromegaly and gigantism patients as well as in the general population of Ireland. nameOfConference DOI: 10.1530/endoabs.38.p304 QMRO: qmroHref Iacovazzo D, Jose S, Bunce B et al. (publicationYear). Unique clinical picture in patients with X-linked acrogigantism. nameOfConference DOI: 10.1530/endoabs.38.p306 QMRO: qmroHref Scagliotti V, Avagliano L, Gualtieri A et al. (2016). Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma. nameOfConference DOI: 10.1007/s11102-015-0682-1 QMRO: qmroHref Kumar S, Yadav RN, Gupta P et al. (2015). Prostatic hyperplasia in acromegaly, a myth or reality: a case–control study. nameOfConference DOI: 10.1530/eje-14-0698e QMRO: qmroHref Hernández-Ramírez LC, Gabrovska P, Dénes J et al. (2015). Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. nameOfConference DOI: 10.1210/jc.2015-1869 QMRO: qmroHref Gan H-W, Bulwer C, Jeelani O et al. (2015). Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. nameOfConference DOI: 10.1186/s13633-015-0011-5 QMRO: qmroHref O'Toole SM, Dénes J, Robledo M et al. (2015). 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas. nameOfConference DOI: 10.1530/erc-15-0241 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/8661 Ferraù F, Korbonits M (2015). Metabolic comorbidities in Cushing's syndrome*. nameOfConference DOI: 10.1530/eje-15-0354 QMRO: qmroHref Niessen SJM, Forcada Y, Mantis P et al. (publicationYear). Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter. nameOfConference DOI: 10.1371/journal.pone.0127794 QMRO: qmroHref Perez-Rivas LG, Theodoropoulou M, Ferraù F et al. (2015). The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. nameOfConference DOI: 10.1210/jc.2015-1453 QMRO: qmroHref Radian S, Jonsson PJ, Camacho-Hubner C et al. (publicationYear). Pituitary apoplexy in GH-deficient adults treated with GH - a KIMS database retrospective study. nameOfConference DOI: 10.1530/endoabs.37.ep805 QMRO: qmroHref Rivas LGP, Theodoropoulou M, Ferrau F et al. (publicationYear). The ubiquitin-specific protease 8 gene is frequently mutated in adenomas causing Cushing's disease. nameOfConference DOI: 10.1530/endoabs.37.oc12.2 QMRO: qmroHref Müller TD, Nogueiras R, Andermann ML et al. (2015). Ghrelin. nameOfConference DOI: 10.1016/j.molmet.2015.03.005 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/13772 Perez-Rivas L, Theodoropoulou M, Ferraù F et al. (publicationYear). The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease.. nameOfConference DOI: 10.1055/s-0035-1547607 QMRO: qmroHref Renukanthan A, Quinton R, Turner B et al. (2015). Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia. nameOfConference DOI: 10.1007/s12020-015-0562-5 QMRO: qmroHref Melmed S, Popovic V, Bidlingmaier M et al. (2015). Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. nameOfConference DOI: 10.1210/jc.2014-4113 QMRO: qmroHref Dénes J, Kasuki L, Trivellin G et al. (publicationYear). Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas. nameOfConference DOI: 10.1371/journal.pone.0117107 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/6951 Lim SV, Marenzana M, Hopkinson M et al. (2015). Excessive Growth Hormone Expression in Male GH Transgenic Mice Adversely Alters Bone Architecture and Mechanical Strength. nameOfConference DOI: 10.1210/en.2014-1572 QMRO: qmroHref Ferreira VM, Marcelino M, Piechnik SK et al. (2015). Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma. nameOfConference DOI: 10.1186/1532-429x-17-s1-p271 QMRO: qmroHref Kumar S, Yadav RN, Gupta P et al. (2015). Prostatic hyperplasia in acromegaly, a myth or reality: a case–control study. nameOfConference DOI: 10.1530/eje-14-0698 QMRO: qmroHref Gardner CJ, Mattsson AF, Daousi C et al. (2015). GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database. nameOfConference DOI: 10.1530/eje-14-0654 QMRO: qmroHref Glynn NGL, Korbonits M (2015). A 25-Year-Old Woman with Headache and Joint Pain. nameOfConference DOI: 10.1007/978-1-4471-2789-5_8 QMRO: qmroHref Iacovazzo D, Piacentini S, Lugli F et al. (2015). A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1. nameOfConference DOI: doi QMRO: qmroHref Dinesen PT, Dal J, Gabrovska P et al. (2015). An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. nameOfConference DOI: 10.1530/edm-14-0105 QMRO: qmroHref Dutta P, Hajela A, Pathak A et al. (2015). Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team. nameOfConference DOI: 10.4103/0028-3886.158210 QMRO: qmroHref Diaz-Cano S, Szyszka P, Weitsman G et al. (2015). Effect of Erlotinib on Proliferation and Steriodogenesis in Primary Cultures of Adrenocortical Carcinoma. nameOfConference DOI: doi QMRO: qmroHref Dénes J, Swords F, Rattenberry E et al. (2015). Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. nameOfConference DOI: 10.1210/jc.2014-3399 QMRO: qmroHref Soh LM, Druce M, Grossman AB et al. (2015). Evaluation of genotype–phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome. nameOfConference DOI: 10.1530/eje-14-0679 QMRO: qmroHref Menon RK, Ferrau F, Kurzawinski TR et al. (2014). Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. nameOfConference DOI: 10.1530/edm-14-0074 QMRO: qmroHref Gan H-W, Bulwer C, Jeelani O et al. (publicationYear). Paediatric pituitary adenomas: rare, complex, and by no means benign. nameOfConference DOI: 10.1530/endoabs.36.oc1.1 QMRO: qmroHref Solomou S, Korbonits M (2014). The role of ghrelin in weight-regulation disorders: Implications in clinical practice. nameOfConference DOI: 10.14310/horm.2002.1551 QMRO: qmroHref Larkin SJ, Ferraù F, Karavitaki N et al. (2014). Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. nameOfConference DOI: 10.1530/eje-14-0545 QMRO: qmroHref Doleschall M, Szabó JA, Pázmándi J et al. (publicationYear). Common Genetic Variants of the Human Steroid 21-Hydroxylase Gene (CYP21A2) Are Related to Differences in Circulating Hormone Levels. nameOfConference DOI: 10.1371/journal.pone.0107244 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12716 Preda V, Korbonits M, Cudlip S et al. (2014). Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. nameOfConference DOI: 10.1530/eje-14-0426 QMRO: qmroHref Ferreira V, Marcelino M, Piechnik S et al. (2014). 122 Cardiac Abnormalities are Common in Patients Diagnosed with Phaeochromocytoma as Detected by Cardiovascular Magnetic Resonance Imaging. nameOfConference DOI: 10.1136/heartjnl-2014-306118.122 QMRO: qmroHref de Kock L, Sabbaghian N, Plourde F et al. (2014). Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. nameOfConference DOI: 10.1007/s00401-014-1285-z QMRO: qmroHref Nölting S, Giubellino A, Tayem Y et al. (2014). Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. nameOfConference DOI: 10.1210/en.2014-1027 QMRO: qmroHref Aflorei ED, Chen C, Klapholz B et al. (publicationYear). Human AIP gene rescue lethality in a Drosophila melanogaster knockout model of AIP orthologue. nameOfConference DOI: 10.1530/endoabs.35.oc12.1 QMRO: qmroHref Dworakowska D, Dudka D, Weistman G et al. (publicationYear). The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells. nameOfConference DOI: 10.1530/endoabs.35.p586 QMRO: qmroHref Tritos NA, Johannsson G, Korbonits M et al. (2014). Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. nameOfConference DOI: 10.1210/jc.2014-1013 QMRO: qmroHref Gadelha MR, Kasuki L, Dénes J et al. (2013). MicroRNAs: Suggested role in pituitary adenoma pathogenesis. nameOfConference DOI: 10.1007/bf03346759 QMRO: qmroHref Korbonits M, Storr H, Kumar AV et al. (2013). Gli adenomi ipofisari familiari: chi dovrebbe essere testato per le mutazioni AIP?. nameOfConference DOI: 10.1007/bf03346038 QMRO: qmroHref Radian S, King P, Korbonits M (publicationYear). Analysis of the AIP gene promoter. nameOfConference DOI: 10.1530/endoabs.34.p314 QMRO: qmroHref Ferreira V, Rodrigues M, Piechnik S et al. (publicationYear). High incidence of cardiac involvement in patients diagnosed with phaeochromocytoma: a clinical study using cardiovascular magnetic resonance imaging. nameOfConference DOI: 10.1530/endoabs.34.p232 QMRO: qmroHref Renukanthan A, Quinton R, Turner B et al. (publicationYear). Kallmann syndrome, gender dysphoria, thrombophilia and multiple sclerosis: a complex case report. nameOfConference DOI: 10.1530/endoabs.34.p91 QMRO: qmroHref Pernicova I, Korbonits M (2014). Metformin--mode of action and clinical implications for diabetes and cancer.. nameOfConference DOI: 10.1038/nrendo.2013.256 QMRO: qmroHref Dworakowska D, Dudka D, Weitsman G et al. (publicationYear). Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation. nameOfConference DOI: 10.1530/endoabs.34.p182 QMRO: qmroHref Iacovazzo D, Morrison P, Foulkes W et al. (publicationYear). RET mutation negative familial medullary thyroid carcinoma: four families and literature review. nameOfConference DOI: 10.1530/endoabs.34.p425 QMRO: qmroHref Stadler M, Tomann L, Storka A et al. (2014). Effects of smoking cessation on β-cell function, insulin sensitivity, body weight, and appetite. nameOfConference DOI: 10.1530/eje-13-0590 QMRO: qmroHref Stadler M, Krššák M, Jankovic D et al. (2014). Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery.. nameOfConference DOI: 10.1111/cen.12146 QMRO: qmroHref Aflorei ED, Korbonits M (2014). Epidemiology and etiopathogenesis of pituitary adenomas. nameOfConference DOI: 10.1007/s11060-013-1354-5 QMRO: qmroHref Cain JW, Miljic D, Popovic V et al. (2010). Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. nameOfConference DOI: 10.1586/eem.10.42 QMRO: qmroHref Ramirez LCH, Ferrau F, Miljic D et al. (2014). Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. nameOfConference DOI: doi QMRO: qmroHref Alband N, Korbonits M (2014). Chapter 23 Familial pituitary tumors. nameOfConference DOI: 10.1016/b978-0-444-59602-4.00023-x QMRO: qmroHref Iacovazzo D, Sampson JR, Morrison PJ et al. (2014). Five families with RET-mutation negative familial medullary thyroid carcinoma: what lies beyond RET?. nameOfConference DOI: doi QMRO: qmroHref Salvatori R, Gabrovska P, Weber A et al. (2014). Founder Effect in Recurring AIP Mutation Causing Familial Isolated Pituitary Adenoma Syndrome. nameOfConference DOI: doi QMRO: qmroHref Iacovazzo D, Morrison PJ, Foulkes W et al. (2014). Four Families with RET-Mutation Negative Familial Medullary Thyroid Carcinoma: What Lies Beyond RET?. nameOfConference DOI: doi QMRO: qmroHref Butz H, Szabo PM, Igaz P et al. (2014). Integrative Analysis of Chromosomal, Trancriptome, Proteomic and Mirnome Data Reveals Involvement of Impaired Developmental Processes in Clinically Non-Functional Pituitary Adenoma Formation. nameOfConference DOI: doi QMRO: qmroHref Schernthaner-Reiter MH, Trivellin G, Nesterova MV et al. (2014). Interaction of AIP with the cAMP-Dependent Protein Kinase (PKA) Pathway and Its Role in Pituitary Tumor Formation. nameOfConference DOI: doi QMRO: qmroHref Tritos NA, Johannsson G, Korbonits M et al. (2014). Long-Term Safety of Growth Hormone (GH) Replacement in Adults with GH Deficiency (GHD) Following Cure of Acromegaly - a Kims (Pfizer International Metabolic Database) Analysis. nameOfConference DOI: doi QMRO: qmroHref Tritos NA, Johannsson G, Korbonits M et al. (2014). Long-Term Safety of Growth Hormone (GH) Replacement in Adults with GH Deficiency (GHD) Following Cure of Acromegaly a Kims (Pfizer International Metabolic Database) Analysis. nameOfConference DOI: doi QMRO: qmroHref Bulwer C, Gan H-W, Ederies A et al. (2014). MANAGING RARE, RESISTANT, MACRO- AND GIANT PROLACTINOMAS CAUSING RAISED INTRACRANIAL PRESSURE (RICP) IN CHILDREN - LESSONS LEARNT AT A SINGLE CENTRE. nameOfConference DOI: doi QMRO: qmroHref Hernandez-Ramirez LC, Gabrovska P, Denes J et al. (2014). Pituitary Adenomas Harboring AIP Mutations Exhibit Phenotype-Genotype Correlation, but No Association with the Germline FGFR4 G388R Variant or Somatic GNAS1 Mutations. nameOfConference DOI: doi QMRO: qmroHref Radian S, Gabrovska P, Holland B et al. (2014). Population Screening for the Irish Founder AIP Mutation R304*Reveals a Prevalence of 1/500 in the Local Population, While High Mutation Frequency Is Present Among Irish Familial and Sporadic Somatotropinoma Patients. nameOfConference DOI: doi QMRO: qmroHref Fliers E, Korbonits M, Romijn JA (2014). Preface. nameOfConference DOI: 10.1016/b978-0-444-59602-4.09984-6 QMRO: qmroHref Dworakowska D, Dudka D, Weitsman G et al. (2014). Simultaneous Targeting PI3K/Akt/mTOR and MEK/RAF/ERK Pathways Results in a Synergistic Anti-Proliferative Effect in an Adrenocortical Carcinoma Model. nameOfConference DOI: doi QMRO: qmroHref Soh LM, Druce M, Grossman AB et al. (2014). Strong Genotype-Phenotype Correlation in Pendred Syndrome Allows Reduced Endocrine Follow-up in Suitable Patients. nameOfConference DOI: doi QMRO: qmroHref Perelberg D, Morillon P, Ederies A et al. (2014). THREE YEAR EXPERIENCE OF A NATIONAL INTERDISCIPLINARY INITIATIVE TO ENHANCE THE MANAGEMENT OF HYPOTHALAMIC PITUITARY AXIS TUMOURS (HPATS) USING MULTI-SITE VIDEOCONFERENCING ON BEHALF OF THE UK HPAT INTEREST GROUP. nameOfConference DOI: doi QMRO: qmroHref Kola B, Wittman G, Bodnár I et al. (2013). The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release.. nameOfConference DOI: 10.1096/fj.13-232918 QMRO: qmroHref Garcia EA, Trivellin G, Aflorei ED et al. (2013). Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?. nameOfConference DOI: 10.1210/jc.2013-2602 QMRO: qmroHref Scerif M, Füzesi T, Thomas JD et al. (2013). CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus.. nameOfConference DOI: 10.1530/JOE-13-0192 QMRO: qmroHref Ribeiro-Oliveira A, Marques MB, Vilas-Boas WW et al. (2015). The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress. nameOfConference DOI: 10.1177/1470320313499199 QMRO: qmroHref Lim S-V, Marenzana M, List E et al. (publicationYear). GH excess in bGH transgenic mice adversely affects bone density, architecture and quality. nameOfConference DOI: 10.1530/boneabs.01.oc2.6 QMRO: qmroHref Aflorei ED, Chen C, Klapholz B et al. (publicationYear). Drosophila melanogaster as a model organism to study aryl hydrocarbon receptor interacting protein gene function. nameOfConference DOI: 10.1530/endoabs.32.p825 QMRO: qmroHref Barry S, Gadaleta E, Chelala C et al. (publicationYear). Gene expression profiling of familial and sporadic pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.32.p823 QMRO: qmroHref Miljic D, Pekic S, Stojanovic M et al. (publicationYear). Genetic and clinical characteristics of Serbian FIPA families. nameOfConference DOI: 10.1530/endoabs.32.p859 QMRO: qmroHref Hernández‐Ramírez LC, Korbonits M (2013). Familial Pituitary Adenomas. nameOfConference DOI: 10.1002/9781118559406.ch10 QMRO: qmroHref Begum F, Trivellin G, Gabrovska P et al. (publicationYear). Creation of a locus-specific database for AIP mutations. nameOfConference DOI: 10.1530/endoabs.31.p254 QMRO: qmroHref Stiles C, Kumar A, Bockenhauer D et al. (2013). De Novo HNF1b mutation as a cause for chronic treatment-resistant hypomagnesaemia. nameOfConference DOI: 10.1530/endoabs.31.p58 QMRO: qmroHref Lim S-V, Marenzana M, List E et al. (publicationYear). Excessive GH expression in bGH transgenic mice adversely alters bone architecture and quality. nameOfConference DOI: 10.1530/endoabs.31.p8 QMRO: qmroHref Barry S, Gadaleta E, Chelala C et al. (publicationYear). Invasion signature' revealed by the analysis of AIP positive and AIP mutation negative human pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.31.p249 QMRO: qmroHref Denes J, Swords F, Rattenberry E et al. (publicationYear). Pituitary adenoma and phaeochromocytoma/paraganglioma - a novel syndrome with a heterogeneous genetic background. nameOfConference DOI: 10.1530/endoabs.31.oc5.8 QMRO: qmroHref Herincs M, Antwi SO, Chahal HS et al. (publicationYear). Prevalence of familial isolated pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.31.p258 QMRO: qmroHref Denes J, Kasuki L, Trivellin G et al. (publicationYear). The role of microRNA miR-34a in the regulation of aryl hydrocarbon receptor interacting protein. nameOfConference DOI: 10.1530/endoabs.31.oc5.2 QMRO: qmroHref Javaid MR, Stone IS, Grossman AB et al. (2013). Cardiac magnetic resonance myocardial feature-tracking: the effect of treatment in patients with adult-onset growth hormone deficiency and acromegaly. nameOfConference DOI: 10.1186/1532-429x-15-s1-e55 QMRO: qmroHref Lim CT, Kola B, Feltrin D et al. (2013). Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism.. nameOfConference DOI: 10.1016/j.mce.2012.11.007 QMRO: qmroHref Rattenberry E, Vialard L, Yeung A et al. (2013). A Comprehensive Next Generation Sequencing-Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma. nameOfConference DOI: 10.1210/jc.2013-1319 QMRO: qmroHref Occhi G, Regazzo D, Trivellin G et al. (2013). A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. nameOfConference DOI: 10.1371/journal.pgen.1003350 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/4902 Kovács GL, Góth M, Rotondo F et al. (2013). ACTH-secreting Crooke cell carcinoma of the pituitary.. nameOfConference DOI: 10.1111/eci.12010 QMRO: qmroHref Javaid MR, Stone I, Grossman A et al. (2013). CARDIAC MAGNETIC RESONANCE MYOCARDIAL FEATURE TRACKING: THE EFFECT OF TREATMENT IN PATIENTS WITH ADULT-ONSET GROWTH HORMONE DEFICIENCY AND ACROMEGALY. nameOfConference DOI: 10.1016/S0167-5273(13)70152-9 QMRO: qmroHref Williams F, Hunter S, Bradley L et al. (2013). Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation.. nameOfConference DOI: 10.1210/jc.2013-2868 QMRO: qmroHref Gadelha MR, Trivellin G, Hernandez-Ramirez LC et al. (2013). Genetics of Pituitary Adenomas. nameOfConference DOI: 10.1159/000345673 QMRO: qmroHref Gueorguiev M, Korbonits M (2013). Genetics of the ghrelin system.. nameOfConference DOI: 10.1159/000348665 QMRO: qmroHref Gadelha MR, Kasuki L, Korbonits M (2013). Novel pathway for somatostatin analogs in patients with acromegaly. nameOfConference DOI: 10.1016/j.tem.2012.11.007 QMRO: qmroHref Martucci F, Trivellin G, Korbonits M (2012). Familial isolated pituitary adenomas: an emerging clinical entity.. nameOfConference DOI: 10.1007/BF03346742 QMRO: qmroHref Nölting S, Garcia E, Alusi G et al. (2012). Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.. nameOfConference DOI: 10.1530/JME-12-0028 QMRO: qmroHref Butz H, Likó I, Czirják S et al. (2012). Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size. nameOfConference DOI: doi QMRO: qmroHref Déenes J, Kovács GL, Patócs A et al. (2012). P01-49 Familial acromegaly and familial prolactinoma cases in Hungary. nameOfConference DOI: 10.1016/s1096-6374(12)60128-2 QMRO: qmroHref Gleeson H, Jönsson P, Clayton P et al. (2012). P03-42 Altered social outcomes in patients growing up with a hypothalamic pituitary condition: Data fromthe KIMS database. nameOfConference DOI: 10.1016/s1096-6374(12)60227-5 QMRO: qmroHref Trivellin G, Butz H, Delhove J et al. (2012). MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.. nameOfConference DOI: 10.1152/ajpendo.00546.2011 QMRO: qmroHref Butz H, Likó I, Czirják S et al. (2012). 2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size. nameOfConference DOI: 10.1515/9783110224641.46 QMRO: qmroHref Korbonits M, Storr H, Kumar AV (2012). Familial pituitary adenomas - who should be tested for AIP mutations?. nameOfConference DOI: 10.1111/j.1365-2265.2012.04445.x QMRO: qmroHref Jeyabalan J, Shah M, Viollet B et al. (2012). Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment.. nameOfConference DOI: 10.1530/JOE-12-0184 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12713 Scerif M, Kola B, Korbonits M (2012). Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues. nameOfConference DOI: 10.1007/978-1-61779-903-7_5 QMRO: qmroHref Thompson IR, Chand AN, King PJ et al. (2012). Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide.. nameOfConference DOI: 10.1530/ERC-12-0129 QMRO: qmroHref Chahal HS, Trivellin G, Leontiou CA et al. (2012). Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.. nameOfConference DOI: 10.1210/jc.2012-1111 QMRO: qmroHref Guaraldi F, Corazzini V, Gallia GL et al. (2012). Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor. nameOfConference DOI: 10.1007/s11102-012-0391-y QMRO: qmroHref Lim CT, Korbonits M (2012). Paediatric endocrine aspects of ghrelin.. nameOfConference DOI: doi QMRO: qmroHref Zemrak F, Thomas J, Dattani A et al. (2012). Cardiovascular changes in patients with acromegaly assessed by CMR.. nameOfConference DOI: 10.1186/1532-429X-14-S1-O85 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/5319 Dattani A, Thomas J, Zemrak F et al. (2012). Cardiovascular changes in patients with adult-onset growth hormone deficiency assessed by CMR.. nameOfConference DOI: 10.1186/1532-429X-14-S1-P192 QMRO: qmroHref Noelting S, Garcia E, Alusi G et al. (2012). Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines. nameOfConference DOI: doi QMRO: qmroHref Boguszewski CL, Fighera TM, Bornschein A et al. (2012). Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma. nameOfConference DOI: 10.1590/S0004-27302012000800008 QMRO: qmroHref Lim CT, Lolli F, Thomas JD et al. (2012). Measurement of AMP-activated protein kinase activity and expression in response to ghrelin.. nameOfConference DOI: 10.1016/B978-0-12-381272-8.00017-9 QMRO: qmroHref Marques MB, Ribeiro-Oliveira AJ, Guimaraes J et al. (2012). Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. nameOfConference DOI: 10.3109/10253890.2011.648673 QMRO: qmroHref Korbonits M (2012). Molecular biology of pituitary tumours. nameOfConference DOI: doi QMRO: qmroHref Alexandraki KI, Munayem Khan M, Chahal HS et al. (2012). Oncogene-induced senescence in pituitary adenomas and carcinomas.. nameOfConference DOI: 10.14310/horm.2002.1358 QMRO: qmroHref Miljic P, Miljic D, Cain JW et al. (2012). Pathogenesis of vascular complications in Cushing's syndrome. nameOfConference DOI: 10.1007/BF03401535 QMRO: qmroHref Diggle CP, Parry DA, Logan CV et al. (2012). Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. nameOfConference DOI: 10.1002/humu.22111 QMRO: qmroHref Morgan RML, Hernández-Ramírez LC, Trivellin G et al. (2012). Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition.. nameOfConference DOI: 10.1371/journal.pone.0053339 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/5372 Butz H, Liko I, Czirjak S et al. (2012). miR expression profile reveals alterations of G2/M transition of cell cycle in pituitary adenomas. nameOfConference DOI: doi QMRO: qmroHref Liu B, Garcia EA, Korbonits M (2011). Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes.. nameOfConference DOI: 10.1016/j.peptides.2011.09.006 QMRO: qmroHref Cai W, Kramarova TV, Berg P et al. (2011). The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor alpha. nameOfConference DOI: 10.1371/journal.pone.0025201 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/5423 Lim CT, Kola B, Korbonits M (2011). The ghrelin/GOAT/GHS-R system and energy metabolism.. nameOfConference DOI: 10.1007/s11154-011-9169-1 QMRO: qmroHref Trivellin G, Korbonits M (2011). AIP and its interacting partners.. nameOfConference DOI: 10.1530/JOE-11-0054 QMRO: qmroHref Wass JAH, Trainer PJ, Korbonits M (2011). Acromegaly. nameOfConference DOI: 10.1093/med/9780199235292.003.2138 QMRO: qmroHref Scerif M, Goldstone AP, Korbonits M (2011). Ghrelin in obesity and endocrine diseases.. nameOfConference DOI: 10.1016/j.mce.2011.02.011 QMRO: qmroHref Butz H, Likó I, Czirják S et al. (2011). MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas.. nameOfConference DOI: 10.1007/s11102-010-0268-x QMRO: qmroHref Stals K, Trivellin G, Korbonits M (2011). AIP Mutation in Pituitary Adenomas REPLY. nameOfConference DOI: doi QMRO: qmroHref Stals K, Trivellin G, Korbonits M (2011). The authors and a colleague reply. nameOfConference DOI: doi QMRO: qmroHref Shah M, Viollet B, Korbonits M et al. (2011). Deletion of Amp-activated Protein Kinase (AMPK)-Alpha 1 catalytic subunit in mice impairs the in vivo response of bones to hormonal challenges. nameOfConference DOI: 10.1016/j.bone.2011.03.139 QMRO: qmroHref Butz H, Liko I, Czirjak S et al. (2011). EXPRESSION OF A SUBSET OF MICRORNAS IN CLINICALLY NON-FUNCTIONING PITUITARY ADENOMAS CORRELATES WITH TUMOR SIZE. nameOfConference DOI: doi QMRO: qmroHref Alexandraki KI, Kaltsas GA, Vouliotis A-I et al. (2011). Specific electrocardiographic features associated with Cushing's disease.. nameOfConference DOI: 10.1111/j.1365-2265.2011.03975.x QMRO: qmroHref Dénes J, Korbonits M, Hubina E et al. (2011). [Familial isolated pituitary adenoma syndrome].. nameOfConference DOI: 10.1556/OH.2011.29093 QMRO: qmroHref Scerif M, Goldstone AP, Korbonits M (2011). Ghrelin in Obesity and Endocrine Diseases.. nameOfConference DOI: 10.1016/j.mce.2011.02.020 QMRO: qmroHref Chahal HS, Stals K, Unterländer M et al. (2011). AIP mutation in pituitary adenomas in the 18th century and today.. nameOfConference DOI: 10.1056/NEJMoa1008020 QMRO: qmroHref Chahal HS, Stals K, Unterlander M et al. (2011). Brief Report: AIP Mutation in Pituitary Adenomas in the 18th Century and Today.. nameOfConference DOI: 10.1056/NEJMoa1008020 QMRO: qmroHref Chahal HS, Ansorge O, Karavitaki N et al. (2011). Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.. nameOfConference DOI: 10.1159/000329195 QMRO: qmroHref Lim CT, Kola B, Grossman A et al. (2011). The expression of ghrelin O-acyltransferase (GOAT) in human tissues.. nameOfConference DOI: 10.1507/endocrj.k11e-117 QMRO: qmroHref Dworakowska D, Korbonits M, Aylwin S et al. (2011). The pathology of pituitary adenomas from a clinical perspective. nameOfConference DOI: 10.2741/s136 QMRO: qmroHref Dworakowska D, Korbonits M, Aylwin S et al. (2011). The pathology of pituitary adenomas from a clinical perspective.. nameOfConference DOI: 10.2741/s136 QMRO: qmroHref Grisouard J, Timper K, Radimerski TM et al. (2010). Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. nameOfConference DOI: 10.1016/j.bcp.2010.08.021 QMRO: qmroHref de Pinho LKJ, Neto LV, Wildemberg LEA et al. (2010). Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. nameOfConference DOI: 10.1590/s0004-27302010000800006 QMRO: qmroHref Butz H, Likó I, Czirják S et al. (2010). Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.. nameOfConference DOI: 10.1210/jc.2010-0581 QMRO: qmroHref Ozfirat Z, Korbonits M (2010). AIP gene and familial isolated pituitary adenomas.. nameOfConference DOI: 10.1016/j.mce.2010.05.001 QMRO: qmroHref Musat M, Morris DG, Korbonits M et al. (2010). Cyclins and their related proteins in pituitary tumourigenesis. nameOfConference DOI: 10.1016/j.mce.2010.03.017 QMRO: qmroHref Butz H, Likó I, Czirják S et al. (2010). Down-Regulation of Wee1 Kinase by a Specific Subset of microRNAs in Human Sporadic Pituitary Adenomas. nameOfConference DOI: 10.1210/mend.24.9.9995 QMRO: qmroHref Dénes J, Korbonits M, Hubina E et al. (2010). [Treatment of acromegaly].. nameOfConference DOI: 10.1556/OH.2010.28877 QMRO: qmroHref Langouche L, Vander Perre S, Thiessen S et al. (2010). Alterations in Adipose Tissue during Critical Illness An Adaptive and Protective Response?. nameOfConference DOI: 10.1164/rccm.200909-1395OC QMRO: qmroHref Shah M, Kola B, Bataveljic A et al. (2010). AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. nameOfConference DOI: 10.1016/j.bone.2010.04.596 QMRO: qmroHref Igreja S, Chahal HS, King P et al. (2010). Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.. nameOfConference DOI: 10.1002/humu.21292 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/13186 Stilling G, Sun ZF, Zhang SY et al. (2010). MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and-493 in pituitary carcinomas. nameOfConference DOI: 10.1007/s12020-010-9346-0 QMRO: qmroHref Chahal HS, Chapple JP, Frohman LA et al. (2010). Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA).. nameOfConference DOI: 10.1016/j.tem.2010.02.007 QMRO: qmroHref Chahal HS, Alband N, Ansorge O et al. (2010). AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.. nameOfConference DOI: doi QMRO: qmroHref Shah⁎ M, Bataveljic A, Arnett TR et al. (2010). AMP-activated protein kinase (AMPK) regulates in vitro bone formation and bone mass in vivo. nameOfConference DOI: 10.1016/j.bone.2010.04.079 QMRO: qmroHref Langouche L, Perre SV, Thiessen S et al. (2010). Alterations in adipose tissue during critical illness: an adaptive and protective response?. nameOfConference DOI: 10.1186/cc8823 QMRO: qmroHref Righi A, Zhang SY, Jin L et al. (2010). Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues. nameOfConference DOI: 10.1007/s12022-009-9096-9 QMRO: qmroHref Gadelha MR, Kasuki L, Neto LV et al. (2010). Pathogenesis of GH-secreting adenomas. nameOfConference DOI: doi QMRO: qmroHref Lim CT, Kola B, Korbonits M (2010). AMPK as a mediator of hormonal signalling.. nameOfConference DOI: 10.1677/JME-09-0063 QMRO: qmroHref Kopchick JJ, Martos-Moreno GÁ, Korbonits M et al. (2010). Chapter 23 Regulation of Growth Hormone and Action (Secretagogues). nameOfConference DOI: 10.1016/b978-1-4160-5583-9.00023-x QMRO: qmroHref Lim CT, Kola B, Korbonits M et al. (2010). Ghrelin's role as a major regulator of appetite and its other functions in neuroendocrinology.. nameOfConference DOI: 10.1016/S0079-6123(10)82008-4 QMRO: qmroHref Tahir A, Chahal HS, Korbonits M (2010). Molecular genetics of the aip gene in familial pituitary tumorigenesis.. nameOfConference DOI: 10.1016/S0079-6123(10)82010-2 QMRO: qmroHref Trivellin G, Lennox C, Cain JW et al. (2010). OR3,18 Clinical, genetic and molecular characterisation of patients with familial isolated pituitary adenomas (FIPA), especially GH-secreting adenomas. nameOfConference DOI: 10.1016/s1096-6374(10)70026-5 QMRO: qmroHref Trivellin G, Bolger GB, Igreja S et al. (2010). The Pathogenic Role of AIP Mutations - The Importance of the Integration of Clinical, Experimental and Modeling Data on Advising Patients and Their Families with Pituitary Adenoma Predisposition.. nameOfConference DOI: doi QMRO: qmroHref Dworakowska D, Wlodek E, Leontiou CA et al. (2009). Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.. nameOfConference DOI: 10.1677/ERC-09-0101 QMRO: qmroHref Butler H, Korbonits M (2009). Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.. nameOfConference DOI: 10.1530/EJE-09-0511 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12711 Grisouard J, Kinter DS, Radimerski T et al. (2009). AMP-activated protein kinase (AMPK) modulates lipopolysaccharide (LPS)-induced cytokine expression and lipolysis in human adipocytes. nameOfConference DOI: doi QMRO: qmroHref Kola B, Korbonits M (2009). Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation.. nameOfConference DOI: 10.1677/JOE-09-0056 QMRO: qmroHref Garcia EA, King P, Sidhu K et al. (2009). The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes.. nameOfConference DOI: 10.1530/EJE-09-0122 QMRO: qmroHref Gueorguiev M, Lecoeur C, Meyre D et al. (2009). Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity.. nameOfConference DOI: 10.1038/oby.2008.589 QMRO: qmroHref Korbonits M, Carlsen E (2009). Recent clinical and pathophysiological advances in non-functioning pituitary adenomas.. nameOfConference DOI: 10.1159/000192449 QMRO: qmroHref Igreja S, Chahal HS, Akker SA et al. (2009). Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations.. nameOfConference DOI: 10.1111/j.1365-2265.2008.03379.x QMRO: qmroHref Gueorguiev M, Lecoeur C, Benzinou M et al. (2009). A genetic study of the ghrelin and growth hormone secretagogue receptor (GHSR) genes and stature.. nameOfConference DOI: 10.1111/j.1469-1809.2008.00484.x QMRO: qmroHref Leontiou CA, Gueorguiev M, Hassan S et al. (2009). AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation. nameOfConference DOI: 10.1159/000178061 QMRO: qmroHref Chahal HS, Kumar VA, Korbonits M (2009). Familial Isolated Pituitary Adenomas. nameOfConference DOI: 10.17925/use.2009.05.1.55 QMRO: qmroHref Chahal HS, Ajith Kumar VA, Korbonits M (2009). Familial isolated pituitary adenomas. nameOfConference DOI: 10.17925/use.2009.05.1.55 QMRO: qmroHref Geoghegan M, Kola B, Eaton S et al. (2009). P015 EFFECT OF GLUTAMINE ADMINISTRATION ON LEUCOCYTE AMP-ACTIVATED PROTEIN KINASE IN CRITICALLY-ILL PATIENTS. nameOfConference DOI: 10.1016/s1744-1161(09)70065-1 QMRO: qmroHref Musat M, Korbonits M, Grossman A (2009). STOP AKTING TO TREAT ENDOCRINE TUMOURS. nameOfConference DOI: 10.4183/aeb.2009.131 QMRO: qmroHref Korbonits M, Besser M (1996). Diagnosis of Growth Hormone Deficiency in Adults. nameOfConference DOI: 10.1159/000185019 QMRO: qmroHref Kola B, Christ-Crain M, Lolli F et al. (2008). Changes in Adenosine 5 '-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing's Syndrome. nameOfConference DOI: 10.1210/jc.2008-1297 QMRO: qmroHref Ribeiro-Oliveira A, Franchi G, Kola B et al. (2008). Protein western array analysis in human pituitary tumours: insights and limitations.. nameOfConference DOI: 10.1677/ERC-08-0003 QMRO: qmroHref Gibson C, Korbonits M (2008). The Yin and Yang of the Ghrelin Gene Products. nameOfConference DOI: 10.2174/187152208787169242 QMRO: qmroHref Ribeiro-Oliveira A, Korbonits M, Grossman AB (2008). The potential role of D-2 dopamine receptors as a target in the management of neuroendocrine tumors. nameOfConference DOI: 10.4161/cbt.7.12.7168 QMRO: qmroHref Garcia EA, Heude B, Petry CJ et al. (2008). Ghrelin receptor gene polymorphisms and body size in children and adults. nameOfConference DOI: 10.1210/jc.2008-0366 QMRO: qmroHref Grisouard J, Radimerski T, Kinter DS et al. (2008). Effects of the AMPK activators AICAR and metformin on basal and insulin-induced glucose-uptake in human adipocytes. nameOfConference DOI: doi QMRO: qmroHref Shah M, Kola B, Sunters A et al. (2008). Neuroendocrine Activation of AMP-activated Protein Kinase (AMPK) in Osteoblasts. nameOfConference DOI: doi QMRO: qmroHref Grozinsky-Glasberg S, Shimon I, Korbonits M et al. (2008). Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. nameOfConference DOI: 10.1677/ERC-07-0288 QMRO: qmroHref Varga M, Rajczy K, Telkes G et al. (2008). HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.. nameOfConference DOI: 10.1093/ndt/gfn111 QMRO: qmroHref Korbonits M, Trainer PJ, Edwards R et al. (1995). Benzodiazepines attenuate the pituitary‐adrenal responses to corticotrophin‐releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome. nameOfConference DOI: 10.1111/j.1365-2265.1995.tb01889.x QMRO: qmroHref Korbonits M, Trainer PJ, Besser GM (1995). The effect of an opiate antagonist on the hormonal changes induced by hexarelin. nameOfConference DOI: 10.1111/j.1365-2265.1995.tb02045.x QMRO: qmroHref Christ-Crain M, Kola B, Lolli F et al. (2008). AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome.. nameOfConference DOI: 10.1096/fj.07-094144 QMRO: qmroHref Leontiou CA, Gueorguiev M, van der Spuy J et al. (2008). The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.. nameOfConference DOI: 10.1210/jc.2007-2611 QMRO: qmroHref Grozinsky-Glasberg S, Grossman AB, Korbonits M (2008). The role of somatostatin analogues in the treatment of neuroendocrine tumours.. nameOfConference DOI: 10.1016/j.mce.2007.10.006 QMRO: qmroHref Zavarella S, Petrone A, Zampetti S et al. (2008). A new variation in the promoter region, the -604 C > T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. nameOfConference DOI: 10.1038/sj.ijo.0803766 QMRO: qmroHref Kola B, Farkas I, Christ-Crain M et al. (2008). The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.. nameOfConference DOI: 10.1371/journal.pone.0001797 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12715 Grisouard J, Radimerski T, Seboek D et al. (2008). AICAR and metformin differently affect basal and insulin-induced glucose-uptake in human adipocytes. nameOfConference DOI: doi QMRO: qmroHref Shah M, Kola B, Sunters A et al. (2008). AMP-activated protein kinase (AMPK) plays a role in osteoblast function. nameOfConference DOI: doi QMRO: qmroHref van Thuijl H, Kola B, Korbonits M (2008). Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase.. nameOfConference DOI: 10.1016/S0083-6729(06)77006-6 QMRO: qmroHref Korbonits M (2008). Obesity and metabolism. Preface.. nameOfConference DOI: 10.1159/isbn.978-3-8055-8430-2 QMRO: qmroHref Grozinsky-Glasberg S, Franchi G, Teng M et al. (2008). Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.. nameOfConference DOI: 10.1159/000111501 QMRO: qmroHref Kola B, Grossman AB, Korbonits M (2008). The role of AMP-activated protein kinase in obesity.. nameOfConference DOI: 10.1159/000115366 QMRO: qmroHref Korbonits M (2007). Frontiers of Hormone Research: Preface. nameOfConference DOI: 10.1159/000115334 QMRO: qmroHref Radimerski T, Seboek D, Kola B et al. (2007). Differential effects of 5AMP-activated protein kinase (AMPK) activation by metformin and AICAR on glucose uptake and lipolysis in human adipocytes. nameOfConference DOI: doi QMRO: qmroHref Christ-Crain M, Kola B, Lolli F et al. (2007). The role of AMP-activated protein kinase in the metabolic syndrome. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Blaine D, Elia M et al. (2007). Metabolic and hormonal changes during the refeeding period of prolonged fasting. nameOfConference DOI: 10.1530/EJE-06-0740 QMRO: qmroHref Gueorguiev M, Wiltshire S, Garcia EA et al. (2007). Examining the candidacy of ghrelin as a gene responsible for variation in adult stature in a United Kingdom population with type 2 diabetes. nameOfConference DOI: 10.1210/jc.2006-2657 QMRO: qmroHref Ewing I, Pedder-Smith S, Franchi G et al. (2007). A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.. nameOfConference DOI: 10.1111/j.1365-2265.2006.02735.x QMRO: qmroHref Samsuddin S, Glyn M, Kola B et al. (2007). A direct effect of ghrelin to augment cardiac AMPK activity is compromised by hyperglycaemia following ischaemia/reperfusion. nameOfConference DOI: doi QMRO: qmroHref Leontiou CA, Franchi G, Korbonits M (2007). Ghrelin in neuroendocrine organs and tumours.. nameOfConference DOI: 10.1007/s11102-007-0023-0 QMRO: qmroHref Higgins SC, Gueorguiev M, Korbonits M (2007). Ghrelin, the peripheral hunger hormone.. nameOfConference DOI: 10.1080/07853890601149179 QMRO: qmroHref Swales KE, Korbonits M, Carpenter R et al. (2006). The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.. nameOfConference DOI: 10.1158/0008-5472.CAN-06-2399 QMRO: qmroHref Christ-Crain M, Stoeckli R, Ernst A et al. (2006). Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients.. nameOfConference DOI: 10.1210/jc.2006-0256 QMRO: qmroHref Jackson JM, Blaine D, Powell-Tuck J et al. (2006). Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man. nameOfConference DOI: 10.1016/j.nut.2006.06.001 QMRO: qmroHref Emery MN, Leontiou C, Bonner SE et al. (2006). PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. nameOfConference DOI: 10.1111/j.1365-2265.2006.02610.x QMRO: qmroHref Zampetti S, Zavarella S, Petrone A et al. (2006). The role of Leu72Met and-604 C > T polymorphisms of the ghrelin gene on insulin resistance in Italian population. nameOfConference DOI: doi QMRO: qmroHref Hubina E, Nanzer AM, Hanson MR et al. (2006). Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.. nameOfConference DOI: 10.1530/eje.1.02213 QMRO: qmroHref Kola B, Boscaro M, Rutter GA et al. (2006). Expanding role of AMPK in endocrinology. nameOfConference DOI: 10.1016/j.tem.2006.05.006 QMRO: qmroHref García EA, Korbonits M (2006). Ghrelin and cardiovascular health.. nameOfConference DOI: 10.1016/j.coph.2005.10.006 QMRO: qmroHref Góth M, Hubina E, Korbonits M (2005). Relationship between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Blaine D, Elia M et al. (2005). Refeeding David Blaine--studies after a 44-day fast.. nameOfConference DOI: 10.1056/NEJM200511243532124 QMRO: qmroHref Bonner SE, Morris DG, Korbonits M et al. (2005). The roles of CyclinE, Jab1 and archipelago in breast cancer cell cycle dysregulation. nameOfConference DOI: doi QMRO: qmroHref Dahia PLM, Ross KN, Wright ME et al. (2005). A HIF1 alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. nameOfConference DOI: 10.1371/journal.pgen.0010008 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/12717 Kola B, Hubina E, Tucci SA et al. (2005). Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. nameOfConference DOI: 10.1074/jbc.C500175200 QMRO: qmroHref Morris DG, Musat M, Czirják S et al. (2005). Differential gene expression in pituitary adenomas by oligonucleotide array analysis.. nameOfConference DOI: 10.1530/eje.1.01937 QMRO: qmroHref Hubina E, Góth M, Korbonits M (2005). [Ghrelin--a hormone with multiple functions].. nameOfConference DOI: doi QMRO: qmroHref Musat M, Korbonits M, Kola B et al. (2005). Enhanced protein kinase B/Akt signalling in pituitary tumours. nameOfConference DOI: 10.1677/erc.1.00949 QMRO: qmroHref Goldstone AP, Patterson M, Kalingag N et al. (2005). Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma.. nameOfConference DOI: 10.1210/jc.2003-032209 QMRO: qmroHref Usmani OS, Belvisi MG, Patel HJ et al. (2005). Theobromine inhibits sensory nerve activation and cough.. nameOfConference DOI: 10.1096/fj.04-1990fje QMRO: qmroHref Góth M, Hubina E, Korbonits M (2005). [Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome].. nameOfConference DOI: doi QMRO: qmroHref KORBONITS MJ, Thorner MO, Gaylinn BD et al. (2005). Growth Hormone–Releasing Hormone, Ghrelin and Growth Hormone Secretagogues: Basic Physiology and Clinical Implications.. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, GROSSMAN AB, Hubina E et al. (2005). Investigation of the intracellular effects of somatostatin analogs in pituitary adenomas. nameOfConference DOI: doi QMRO: qmroHref Hubina E, Ruscica M, Nanzer AM et al. (2005). Novel molecular aspects of pituitary adenomas.. nameOfConference DOI: doi QMRO: qmroHref KORBONITS MJ, Barnes PJ, Korbonits D et al. (2005). Theobromine inhibits sensory nerve activation and cough. nameOfConference DOI: 10.1096/fj.04-1990fje QMRO: qmroHref Korbonits M, Kipnes M, Grossman AB (2004). Striant (TM) SR: a novel, effective and convenient testosterone therapy for male hypogonadism. nameOfConference DOI: 10.1111/j.1368-5031.2004.000383.x QMRO: qmroHref Tucci SA, Rogers EK, Korbonits M et al. (2004). The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. nameOfConference DOI: 10.1038/sj.bjp.0705968 QMRO: qmroHref Usmani OS, Belvisi MG, Patel HJ et al. (2004). Theobromine inhibits sensory nerve activation and cough. nameOfConference DOI: 10.1096/fj.04-1990fje QMRO: qmroHref Nanzer AM, Khalaf S, Mozid AM et al. (2004). Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway.. nameOfConference DOI: 10.1530/eje.0.1510233 QMRO: qmroHref Korbonits M, Grossman AB (2004). Ghrelin: update on a novel hormonal system. nameOfConference DOI: 10.1530/eje.0.151s067 QMRO: qmroHref Gueorguiev M, Lecoeur C, Froguel R et al. (2004). Mutational analysis of ghrelin and the growth hormone secretagogue receptor. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Slawik M, Cullen D et al. (2004). A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.. nameOfConference DOI: 10.1210/jc.2003-030319 QMRO: qmroHref Góth M, Korbonits M (2004). [Therapy in acromegaly].. nameOfConference DOI: doi QMRO: qmroHref Goldstone AP, Thomas EL, Brynes AE et al. (2004). Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance.. nameOfConference DOI: 10.1210/jc.2003-031118 QMRO: qmroHref Korbonits M, Goldstone AP, Gueorguiev M et al. (2004). Ghrelin - a hormone with multiple functions. nameOfConference DOI: 10.1016/j.yfrne.2004.03.002 QMRO: qmroHref KORBONITS MJ, Hubina E, Goth MI (2004). Aetiology and demography of patients with GH deficiency in KIMS. nameOfConference DOI: doi QMRO: qmroHref Grossman AB, Korbonits M (2004). Akting and cycling: a tale of the pituitary.. nameOfConference DOI: 10.1159/000080512 QMRO: qmroHref Bonner SE, Morris DG, Korbonits M et al. (2004). Cell cycle dysregulation in breast cancer - the roles of Jab1 and Archipelago.. nameOfConference DOI: doi QMRO: qmroHref Musat M, Vax VV, Borboli N et al. (2004). Cell cycle dysregulation in pituitary oncogenesis. nameOfConference DOI: 10.1159/000079037 QMRO: qmroHref Vax V, Goncharov N, Kadashev B et al. (2004). Gonadotropinomas & non-functioning pituitary tumours in males. nameOfConference DOI: doi QMRO: qmroHref KORBONITS MJ, Grossman AB (2004). Non-growth hormone endocrine actions of ghrelin. nameOfConference DOI: 10.1007/1-4020-7971-0_6 QMRO: qmroHref Korbonits M, Morris DG, Nanzer A et al. (2004). Role of regulatory factors in pituitary tumour formation.. nameOfConference DOI: 10.1159/000079038 QMRO: qmroHref Morris DG, Kola B, Borboli N et al. (2003). Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.. nameOfConference DOI: 10.1210/jc.2002-022048 QMRO: qmroHref Korbonits M, Trainer PJ, Nelson ML et al. (1996). Differential stimulation of corticol and dehydropiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. nameOfConference DOI: 10.1046/j.1365-2265.1996.8550865.x QMRO: qmroHref Korbonits M, Trainer PJ, Little JA et al. (1997). Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity. nameOfConference DOI: 10.1046/j.1365-2265.1997.1820979.x QMRO: qmroHref Kola B, Korbonits M, Diaz-Cano S et al. (2003). Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.. nameOfConference DOI: 10.1046/j.1365-2265.2003.01851.x QMRO: qmroHref Vax VV, Gueorguiev M, Dedov II et al. (2003). The Krüppel-like transcription factor 6 gene in sporadic pituitary tumours.. nameOfConference DOI: 10.1677/erc.0.0100397 QMRO: qmroHref Vax VV, Bibi R, Diaz-Cano S et al. (2003). Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.. nameOfConference DOI: 10.1677/joe.0.1780301 QMRO: qmroHref Mozid AM, Tringali G, Forsling ML et al. (2003). Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin.. nameOfConference DOI: 10.1055/s-2003-41801 QMRO: qmroHref Orkin RD, New DI, Norman D et al. (2003). Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. nameOfConference DOI: 10.1007/BF03347357 QMRO: qmroHref Svensson J, Monson JP, Vetter T et al. (2003). Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. nameOfConference DOI: 10.1046/j.1365-2265.2003.01754.x QMRO: qmroHref KORBONITS MJ, Grossman AB, Kola B et al. (2003). Expression of the F-box protein Skp-2 in normal and tumorous pituitary. nameOfConference DOI: doi QMRO: qmroHref KORBONITS MJ, Grossman AB, Bandeira F et al. (2003). Hyperprolactinaemia. nameOfConference DOI: doi QMRO: qmroHref Pyle ME, Korbonits M, Gueorguiev M et al. (2003). Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei.. nameOfConference DOI: 10.1677/joe.0.1760103 QMRO: qmroHref Kaltsas GA, Kola B, Borboli N et al. (2002). Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours.. nameOfConference DOI: 10.1046/j.1365-2265.2002.01643.x QMRO: qmroHref Korbonits M, Gueorguiev M, O'Grady E et al. (2002). A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children.. nameOfConference DOI: 10.1210/jcem.87.8.8881 QMRO: qmroHref Gueorguiev M, Korbonits M, O'Grady E et al. (2002). Mutation in the ghrelin gene associated with increase in body weight and reduction of insulin secretion in tall, obese children. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Grossman AB (2002). Cell Cycle Dysregulation in Human Pituitary Tumours. nameOfConference DOI: 10.1042/cs103022pa QMRO: qmroHref Korbonits M, Chahal HS, Kaltsas G et al. (2002). Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.. nameOfConference DOI: 10.1210/jcem.87.6.8517 QMRO: qmroHref Gnanapavan S, Kola B, Bustin SA et al. (2002). The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. nameOfConference DOI: 10.1210/jcem.87.6.8739 QMRO: qmroHref Newell-Price J, Morris DG, Drake WM et al. (2002). Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. nameOfConference DOI: 10.1210/jcem.87.4.8357 QMRO: qmroHref Isidori AM, Kaltsas GA, Korbonits M et al. (2002). Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease.. nameOfConference DOI: 10.1210/jcem.87.4.8382 QMRO: qmroHref Musat M, Korbonits M, Pyle M et al. (2002). The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.. nameOfConference DOI: 10.1023/a:1025325832698 QMRO: qmroHref KORBONITS MJ (2002). Tumours and Humors. nameOfConference DOI: doi QMRO: qmroHref Korbonits M (1998). Leptin and the thyroid — A puzzle with missing pieces. nameOfConference DOI: 10.1046/j.1365-2265.1998.00594.x QMRO: qmroHref Korbonits M, Kaltsas G, Perry LA et al. (1999). Hexarelin as a test of pituitary reserve in patients with pituitary disease. nameOfConference DOI: 10.1046/j.1365-2265.1999.00828.x QMRO: qmroHref Kaltsas GA, Korbonits M, Isidori AM et al. (2000). How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. nameOfConference DOI: 10.1046/j.1365-2265.2000.01117.x QMRO: qmroHref Korbonits, Little, Forsling et al. (1999). The Effect of Growth Hormone Secretagogues and Neuropeptide Y on Hypothalamic Hormone Release from Acute Rat Hypothalamic Explants. nameOfConference DOI: 10.1046/j.1365-2826.1999.00353.x QMRO: qmroHref Korbonits M, Bujalska I, Shimojo M et al. (2001). Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: Induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. nameOfConference DOI: 10.1210/jcem.86.6.7563 QMRO: qmroHref Korbonits M, Bustin SA, Kojima M et al. (2001). Ghrelin, the endogenous ligand to the growth hormone secretagogue receptor — expression in human hypothalamus and pituitary. nameOfConference DOI: 10.1016/s1096-6374(01)80037-x QMRO: qmroHref Korbonits M, Chitnis MM, Gueorguiev M et al. (2001). The release of leptin and its effect on hormone release from human pituitary adenomas.. nameOfConference DOI: 10.1046/j.1365-2265.2001.01279.x QMRO: qmroHref Kaltsas GA, Korbonits M, Isidori AM et al. (2001). How Common Are Polycystic Ovaries and the Polycystic Ovarian Syndrome in Women With Cushing’s Syndrome?. nameOfConference DOI: 10.1097/00006254-200103000-00018 QMRO: qmroHref Kaltsas G, Korbonits M, Heintz E et al. (2001). Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. nameOfConference DOI: 10.1210/jcem.86.2.7194 QMRO: qmroHref Korbonits M, Kojima M, Kangawa K et al. (2001). Presence of ghrelin in normal and adenomatous human pituitary.. nameOfConference DOI: 10.1385/ENDO:14:1:101 QMRO: qmroHref Korbonits M, Bustin SA, Kojima M et al. (2001). The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors.. nameOfConference DOI: 10.1210/jcem.86.2.7190 QMRO: qmroHref KORBONITS MJ, Grossman AB, Bonthron DT et al. (2001). Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. nameOfConference DOI: 10.1172/JCI11887 QMRO: qmroHref KORBONITS MJ, Gueorguiev M, Goth MI (2001). Leptin and puberty - a review. nameOfConference DOI: 10.1023/a:1012943029127 QMRO: qmroHref Korbonits M, Chitnis MM, Gueorguiev M et al. (2001). Leptin in pituitary adenomas--a novel paracrine regulatory system.. nameOfConference DOI: 10.1023/a:1012934710471 QMRO: qmroHref Putignano P, Kaltsas GA, Korbonits M et al. (2000). Alterations in Serum Protein Levels in Patients with Cushing’s Syndrome before and after Successful Treatment. nameOfConference DOI: 10.1210/jcem.85.9.6833 QMRO: qmroHref Jordan S, Lidhar K, Korbonits M et al. (2000). Cyclin D and cyclin E expression in normal and adenomatous pituitary. nameOfConference DOI: 10.1530/eje.0.143r001 QMRO: qmroHref Skelly RH, Korbonits M, Grossman A et al. (2000). Expression of the Pituitary Transcription Factor Ptx-1, But Not That of the Trans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreasedα -Subunit Secretion1. nameOfConference DOI: 10.1210/jcem.85.7.6683 QMRO: qmroHref Korbonits M, Grossman AB (2000). Drug-induced hyperprolactinaemia. nameOfConference DOI: doi QMRO: qmroHref Lidhar K, Korbonits M, Jordan S et al. (1999). Low Expression of the Cell Cycle Inhibitor p27Kip1 in Normal Corticotroph Cells, Corticotroph Tumors, and Malignant Pituitary Tumors. nameOfConference DOI: 10.1210/jcem.84.10.6066 QMRO: qmroHref Korbonits M, Kaltsas G, Perry LA et al. (1999). The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin. nameOfConference DOI: 10.1210/jcem.84.7.5811 QMRO: qmroHref Satta MA, Korbonits M, Jacobs RA et al. (1999). Expression of menin gene mRNA in pituitary tumours. nameOfConference DOI: 10.1530/eje.0.1400358 QMRO: qmroHref Korbonits M, Ciccarelli E, Ghigo E et al. (1999). The growth hormone secretagogue receptor. nameOfConference DOI: 10.1016/s1096-6374(99)80019-7 QMRO: qmroHref Korbonits M, Adams EF, Grossman AB (1999). Chapter 7 The Effects of GH-Secretagogues on Human Pituitary Cells in Culture and on Rat Hypothalamic Tissue. nameOfConference DOI: 10.1016/b978-044482933-7/50036-6 QMRO: qmroHref Adams EF, Arvat E, Barkan AL et al. (1999). Contributing Authors. nameOfConference DOI: 10.1016/b978-044482933-7/50029-9 QMRO: qmroHref Korbonits M (1998). Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. nameOfConference DOI: 10.1210/jc.83.10.3624 QMRO: qmroHref Trainer PJ, Woods RJ, Korbonits M et al. (1998). The Pathophysiology of Circulating Corticotropin-Releasing Hormone-Binding Protein Levels in the Human. nameOfConference DOI: 10.1210/jcem.83.5.4751 QMRO: qmroHref Korbonits M, Little JA, Trainer PJ et al. (1998). The effect of growth hormone secretagogues on the release of growth hormone-releasing hormone, somatostatin, vasopressin, and corticotrophin-releasing hormone from the rat hypothalamus in vitro. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Grossman AB (1996). Growth hormone-releasing peptides (GHRP) and their analogues.. nameOfConference DOI: doi QMRO: qmroHref Korbonits M, Trainer PJ, Fanciulli G et al. (1996). l-Arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide. nameOfConference DOI: 10.1530/eje.0.1350543 QMRO: qmroHref Korbonits M, Little JA, Camacho-Hübner C et al. (1996). Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.. nameOfConference DOI: doi QMRO: qmroHref Savage M, Korbonits M, Grossman (1996). Intérêt clinique des neuropeptides GHRH et GHRP. nameOfConference DOI: 10.1016/0929-693x(96)86022-2 QMRO: qmroHref Korbonits M, Grossman AB (1995). Growth hormone-releasing peptide and its analogues Novel stimuli to growth hormone release. nameOfConference DOI: 10.1016/1043-2760(94)00204-h QMRO: qmroHref Grossman A, Tsagarakis S, Korbonits M et al. (1993). 17 Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method. nameOfConference DOI: 10.1016/b978-0-12-185281-8.50023-5 QMRO: qmroHref Arimura A, Banks WA, Beaudet A et al. (1993). Contributors to Volume 16. nameOfConference DOI: 10.1016/b978-0-12-185281-8.50004-1 QMRO: qmroHref Grossman A, Tsagarakis S, Korbonits M et al. (1993). Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method. nameOfConference DOI: 10.1016/B978-0-12-185281-8.50023-5 QMRO: qmroHref SELMECI L, KESZLER P, POSCH E et al. (1986). EFFECT OF PARTIALLY PURIFIED ERYTHROCYTE EXTRACT ON THE ELECTROLYTE EXCRETION IN RATS. nameOfConference DOI: doi QMRO: qmroHref Sponsors Barts Charity Pfizer Wellcome Trust Rosetrees Trust Novartis UK Clinical Research Council Medical Research Council Society for Endocrinology Diabetes UK William Harvey Research Foundation CollaboratorsInternal Prof Paul Chapple Dr Ezra Aksoy Dr Sian Henson Dr Carlos Gaston Massuet Prof Fran Balkwill Dr Valentina Cipriani Dr Matthew Traylor Prof Ashley Grossman External David Scott-Coombes (Cardiff) Members of the International FIPA Consortium News Genetic aspects of pituitary tumors: A conversation with Márta Korbonits, MD, PhD, DSc (Healio News), July 2023 Barts Pituitary Centre Programme Grant from Barts Charity [PDF 1,872KB]This large collaborative Programme grant is to discover novel genetic aspects of hypothalamo-pituitary diseases (July 2020) Daily diabetes pill which costs just 15p could end the dreaded 'moon face' side effect of steroid medication which causes the face to swell up(Daily Mail), March 2020 Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial (Lancet Diabetes and Endocrinology), February 2020 Metformin: the white knight fighting corticosteroid side-effects(Lancet Diabetes and Endocrinology), February 2020 Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors (JCEM), January 2020 New gene causing diabetes and insulinomatosis(PNAS), January 2018 Genes of Irish giant still writ large in Ulster(The Sunday Times), September 2016 Genes of an 18th century ‘giant’ could change the lives of 21st-century patients (Guardian), January 2011 Disclosures Society for Endocrinology – President Hungarian Society of Endocrinology and Metabolism - Executive comm member Endocrine-related cancer – Deputy Chief Editor Research funding - Ono, Pfizer and Crinetics Scientific consultant - Pfizer, Ipsen, Novo Nordisk, Ono, Crinetics, Corcept Speaker fee - Ipsen, Novo Nordisk, Recordati Back to top